

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAVXR1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAPLUS and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN      Welcome Banner and News Items  
NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 17:27:38 ON 17 JUN 2008

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 17:28:17 ON 17 JUN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 JUN 2008 HIGHEST RN 1028528-04-2

DICTIONARY FILE UPDATES: 16 JUN 2008 HIGHEST RN 1028528-04-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\pyrazol.str



```

ring nodes :
1  2  3  4  5  6  7  8  9  10 11 12 13 14 15 16 17 18 19 20 21 22 23
24
chain bonds :
7-11 15-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 11-12 11-15 12-13 12-22
13-14 13-24 14-15 16-17 16-21 17-18 18-19 19-20 20-21 22-23 23-24
exact/norm bonds :
11-12 11-15 12-13 12-22 13-14 13-24 14-15 22-23 23-24
exact bonds :
7-11 15-16
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 16-17 16-21 17-18 18-19
19-20 20-21

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom


```

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s L1

SAMPLE SEARCH INITIATED 17:29:20 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 28 TO ITERATE

100.0% PROCESSED 28 ITERATIONS

22 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
 BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 243 TO 877


PROJECTED ANSWERS: 159 TO 721

L2 22 SEA SSS SAM L1

=> D L1

L1 HAS NO ANSWERS


L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> D L2

L2 ANSWER 1 OF 22 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 737791-24-1 REGISTRY  
ED Entered STN: 02 Sep 2004  
CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-ethoxy- (CA INDEX NAME)  
MF C23 H22 N4 O  
SR CA  
LC STN Files: CA, CAPLUS, CASREACT



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d L2 ide\  
'IDE\' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

REG - RN  
SAM - Index Name, MF, and structure - no RN  
FIDE - All substance data, except sequence data  
IDE - FIDE, but only 50 names  
SQIDE - IDE, plus sequence data  
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used  
SQD - Protein sequence data, includes RN  
SQD3 - Same as SQD, but 3-letter amino acid codes are used  
SQN - Protein sequence name information, includes RN  
  
CALC - Table of calculated properties  
EPROP - Table of experimental properties  
PROP - EPROP and CALC

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract  
APPS -- Application and Priority Information  
BIB -- CA Accession Number, plus Bibliographic Data  
CAN -- CA Accession Number

CBIB -- CA Accession Number, plus Bibliographic Data (compressed)  
IND -- Index Data  
IPC -- International Patent Classification  
PATS -- PI, SO  
STD -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels  
IBIB -- BIB, indented, with text labels  
ISTD -- STD format, indented

OBIB ----- AN, plus Bibliographic Data (original)  
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations  
SIBIB ----- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.


The MAX format is the same as ALL.

The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.  
HELP FORMATS -- To see detailed descriptions of the predefined formats.  
ENTER DISPLAY FORMAT (IDE):ide

L2 ANSWER 1 OF 22 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 737791-24-1 REGISTRY  
ED Entered STN: 02 Sep 2004  
CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-ethoxy- (CA INDEX NAME)  
MF C23 H22 N4 O  
SR CA  
LC STN Files: CA, CAPLUS, CASREACT




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d l2 ide

L2 ANSWER 1 OF 22 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 737791-24-1 REGISTRY


ED Entered STN: 02 Sep 2004  
 CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-ethoxy- (CA INDEX NAME)  
 MF C23 H22 N4 O  
 SR CA  
 LC STN Files: CA, CAPLUS, CASREACT



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> d l1 1-22 ide  
 L1 HAS NO ANSWERS  
 'IDE ' IS NOT A VALID STRUCTURE FORMAT KEYWORD  
 Structure Formats  
 SIA ----- Structure Image, Attributes, and map table if it contains  
                   data. (Default)  
 SIM ----- Structure Image.  
 SAT ----- Structure ATtributes and map table if it contains data.  
 SCT ----- Structure Connection Table and map table if it contains  
                   data.  
 SDA ----- All Structure Data (image, attributes, connection table and  
                   map table if it contains data).  
 NOS ----- NO Structure data.  
 ENTER STRUCTURE FORMAT (SIM), NOS:sim  
 L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> d 12 2

L2 ANSWER 2 OF 22 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 737791-22-9 REGISTRY  
ED Entered STN: 02 Sep 2004  
CN Quinoline, 7-chloro-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)  
MF C20 H15 Cl N4  
SR CA  
LC STN Files: CA, CAPLUS, CASREACT




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d 12 22

L2 ANSWER 22 OF 22 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 476474-60-9 REGISTRY  
ED Entered STN: 17 Dec 2002  
CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-8-fluoro- (CA INDEX NAME)  
OTHER NAMES:  
CN 8-Fluoro-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline  
MF C21 H17 F N4  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


2 REFERENCES IN FILE CA (1907 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)



=> d 12 5

L2 ANSWER 5 OF 22 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 700874-60-8 REGISTRY  
ED Entered STN: 29 Jun 2004  
CN L-Glutamic acid, N-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]- (CA INDEX NAME)  
FS STEREOSEARCH  
MF C32 H27 N5 O5  
CI COM  
SR CA

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


=> S FULL L1  
FULL SEARCH INITIATED 17:36:00 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 799 TO ITERATE

100.0% PROCESSED 799 ITERATIONS 569 ANSWERS  
SEARCH TIME: 00.00.01

L3 569 SEA SSS FUL L1

=> d L3 500

L3 ANSWER 500 OF 569 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 476475-38-4 REGISTRY  
ED Entered STN: 17 Dec 2002  
CN Quinoline, 6-(1,3-benzodioxol-5-yl)-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)  
OTHER NAMES:  
CN 6-Benzo[1,3]dioxol-5-yl-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline  
MF C28 H22 N4 O2  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> S L1 SSS FULL  
FULL SEARCH INITIATED 17:41:46 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 799 TO ITERATE

100.0% PROCESSED 799 ITERATIONS 569 ANSWERS  
SEARCH TIME: 00.00.01

L4 569 SEA SSS FUL L1

=> enter CAPLUS  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 380.38 380.59

FILE 'CAPLUS' ENTERED AT 17:42:12 ON 17 JUN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Jun 2008 VOL 148 ISS 25  
FILE LAST UPDATED: 16 Jun 2008 (20080616/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> S L4  
L5 9 L4

=> d scan

L5 9 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN  
IC ICM C07D487-04  
ICS A61K031-4709; A61P009-04  
CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))  
Section cross-reference(s): 1, 63  
TI Preparation of substituted pyrrolo[1,2-b]pyrazoles as mixed lineage kinase  
modulators  
ST mixed lineage kinase modulator pyrrolopyrazole quinoline prepn  
IT Heart, disease  
(failure; preparation of substituted pyrrolo[1,2-b]pyrazoles as mixed  
lineage kinase modulators)  
IT Cardiovascular agents  
Human  
(preparation of substituted pyrrolo[1,2-b]pyrazoles as mixed lineage kinase  
modulators)  
IT 391680-74-3, Protein kinase MLK7  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(preparation of substituted pyrrolo[1,2-b]pyrazoles as mixed lineage kinase  
modulators)  
IT 700872-48-6P, 3-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-  
b]pyrazol-3-yl]quinolin-7-yl]phenyl]propionic Acid trifluoroacetate  
700872-67-9P, 4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-  
b]pyrazol-3-yl]quinolin-7-yl]benzoic acid 700874-15-3P,  
[2-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-  
yl]quinolin-7-yl]benzoylamino]ethyl]carbamic acid tert-butyl ester  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
(Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of substituted pyrrolo[1,2-b]pyrazoles as mixed lineage kinase  
modulators)  
IT 700871-90-5P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-  
yl]-7-thiophen-2-ylquinoline trifluoroacetate 700871-92-7P,  
7-(4-Methylthiophene-2-yl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-  
b]pyrazol-3-yl]quinoline Trifluoroacetate 700871-94-9P  
700871-96-1P, 7-Phenyl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-  
pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700871-98-3P  
700872-00-0P 700872-02-2P 700872-04-4P  
700872-06-6P 700872-08-8P 700872-10-2P,  
7-(3-Chlorophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-  
b]pyrazol-3-yl]quinoline trifluoroacetate 700872-12-4P,  
7-(4-Chlorophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-  
b]pyrazol-3-yl]quinoline trifluoroacetate 700872-14-6P,  
7-(3-Nitrophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-  
3-yl]quinoline trifluoroacetate 700872-16-8P,  
7-(4-Nitrophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-  
3-yl]quinoline trifluoroacetate 700872-18-0P  
700872-20-4P, N-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-  
b]pyrazol-3-yl]quinolin-7-yl]phenyl]methanesulfonamide trifluoroacetate  
700872-22-6P, 7-(2-Ethoxyphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-  
4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate  
700872-24-8P, 7-(3-Ethoxyphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-  
4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate  
700872-26-0P, 7-(4-Ethoxyphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-  
4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate  
700872-28-2P, 7-(4-Methoxyphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-  
4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate  
700872-30-6P, 7-(4-Fluoro-3-methylphenyl)-4-[2-(pyridin-2-yl)-5,5-  
dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate

700872-32-8P, 7-(4-Fluoro-2-methylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate  
 700872-34-6P, 7-(4-Bromophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-36-2P  
 , 7-(4-Ethylsulfanylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-38-4P,  
 7-(4-Methylsulfanylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-40-8P,  
 4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzonitrile trifluoroacetate 700872-42-0P  
 700872-44-2P, 1-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]ethanone trifluoroacetate  
 700872-46-4P, 2-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]benzamide trifluoroacetate  
 700872-50-0P, 7-(3,5-Dichlorophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate  
 700872-52-2P, 7-(4-Methoxy-3-methylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate  
 700872-54-4P 700872-56-6P 700872-58-8P  
 700872-60-2P, 7-(2-Nitrophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-62-4P  
 700872-64-6P, 7-(4-(Methanesulfinyl)phenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate  
 700872-66-8P, 7-Benzo[1,3]dioxol-5-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate  
 700872-68-0P, 4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoic Acid trifluoroacetate  
 700872-70-4P, 7-(3,5-Bis-trifluoromethylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate  
 700872-72-6P, 3-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoic acid trifluoroacetate  
 700872-74-8P, 2-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoic acid trifluoroacetate  
 700872-76-0P, 7-(4-Isobutylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate  
 700872-78-2P, [4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenoxy]acetic Acid trifluoroacetate  
 700872-80-6P, 7-Benzo[b]thiophene-2-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate  
 700872-82-8P, 7-Benzofuran-2-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-84-0P  
 , 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[thiophene-3-yl]quinoline trifluoroacetate 700872-86-2P,  
 7-Furan-3-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-88-4P, 7-(4-Methyl-3-nitrophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-90-8P, 7-(4-Cyclohexylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline Trifluoroacetate 700872-92-6P,  
 7-[4-(Benzo[b]thiophene-3-yl)phenyl]-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-93-1P  
 , 7-(3,4-Dichlorophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 700872-94-2P, 4-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoic acid 700872-95-3P, 3-[4-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]propionic acid 700872-96-4P, 7-(4-Fluorophenyl)-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 700872-97-5P,  
 7-(4-Methoxyphenyl)-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 700872-99-7P, 7-Phenyl-4-[2-(6-

methypyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700873-01-4P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[thiophene-2-yl]quinoline trifluoroacetate 700873-02-5P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(3-nitrophenyl)quinoline 700873-03-6P, 7-(4-Chlorophenyl)-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 700873-05-8P, 7-Furan-2-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700873-07-0P 700873-09-2P 700873-11-6P 700873-13-8P 700873-15-0P 700873-17-2P 700873-19-4P, 7-Cyclohexyl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700873-22-9P 700873-24-1P, [4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]acetic acid trifluoroacetate 700873-26-3P, 7-(4-(Methanesulfonyl)phenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700873-28-5P 700873-30-9P 700873-32-1P 700873-34-3P, 5-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]isophthalic acid trifluoroacetate 700873-36-5P 700873-38-7P, 7-(2,2-Dioxo-2,3-dihydro-1H-benzo[c]thiophene-5-yl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700873-40-1P 700873-42-3P 700873-45-6P, 7-(6-Methoxypyridazin-3-yl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline difluoroacetate 700873-47-8P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[pyrimidin-2-yl]quinoline difluoroacetate 700873-49-0P, 4-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]butyramide trifluoroacetate 700873-51-4P 700873-53-6P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[pyrimidin-5-yl]quinoline difluoroacetate 700873-55-8P 700873-57-0P 700873-59-2P, 5-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]thiophene-2-sulfonic acid amide trifluoroacetate 700873-61-6P 700873-63-8P 700873-64-9P, 4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzenesulfonamide 700873-65-0P, 3-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzenesulfonamide 700873-66-1P, 2-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzenesulfonamide 700873-68-3P 700873-71-8P 700873-73-0P, 7-Pyrazol-1-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700873-75-2P 700873-76-3P, 4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]piperazine-1-carboxylic acid tert-butyl ester 700873-78-5P, 7-Piperidin-1-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 700873-80-9P 700873-81-0P, 3-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]propionic acid methyl ester 700873-83-2P, 3-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]propionamide 700873-85-4P 700873-88-7P 700873-91-2P 700873-93-4P 700873-96-7P 700873-98-9P 700874-01-7P 700874-04-0P 700874-07-3P 700874-09-5P, 7-[4-(2-Methoxyethoxy)phenyl]-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700874-11-9P, 7-[4-(2-Fluoroethoxy)phenyl]-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700874-14-2P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(2,2,2-trifluoroethoxy)phenyl]quinoline trifluoroacetate 700874-17-5P, Piperidin-1-yl[4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-

pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]methanone  
 700874-18-6P, [4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]thiomorpholin-4-ylmethanone  
 700874-20-6P, Morpholin-4-yl[4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]methanone  
 700874-22-2P, N-Carbamoylmethyl-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-23-3P  
 , N-[2-(Isopropylamino)ethyl]-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-24-4P,  
 N-[2-(tert-Butylsulfanyl)ethyl]-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-26-6P,  
 3-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoylamino]propionic Acid Ethyl Ester  
 700874-28-8P, N-(1,1-Dioxotetrahydrothiophene-3-yl)-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-30-2P, 3-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoylamino]piperidine-1-carboxylic acid tert-butyl ester 700874-32-4P  
 700874-34-6P, N-(2-(Morpholin-4-yl)ethyl)-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide  
 700874-36-8P, (1,1-Dioxothiophene-3-yl)[4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]methanone  
 700874-38-0P 700874-40-4P 700874-42-6P,  
 N,N-Dimethyl-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-44-8P, 3-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoylamino]propionic acid tert-butyl ester 700874-46-0P,  
 N-Methyl-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-48-2P, N-[2-(Methanesulfonyl)ethyl]-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-50-6P,  
 N-[(Dimethylamino)methylene]-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-52-8P,  
 4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-55-1P 700874-57-3P  
 700874-59-5P 700874-61-9P 700874-69-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted pyrrolo[1,2-b]pyrazoles as mixed lineage kinase modulators)

IT 78-94-4, Methyl vinyl ketone, reactions 591-19-5, 3-Bromoaniline  
 701-34-8, 4-Bromobenzenesulfonamide 934-60-1, 6-Methylpyridine-2-carboxylic Acid 1765-93-1, 4-Fluorophenylboronic acid 4584-46-7,  
 2-Dimethylaminoethyl chloride hydrochloride 4635-59-0, 4-Chlorobutyryl chloride 5350-57-2, Benzophenone hydrazone 6165-68-0,  
 Thiophene-2-boronic acid 6226-25-1 7565-57-3, Cyclohexylzinc bromide 26510-52-1 34743-88-9, 2-(4-Bromophenoxy)ethanol 57260-71-6  
 57260-73-8, (2-Aminoethyl)carbamic acid tert-butyl ester 73183-34-3  
 82121-06-0, 7-Bromoquinolin-4-ol 118486-94-5, Tri-(n-butyl)(furan-2-yl)stannane 135884-31-0, 1-(tert-Butoxycarbonyl)pyrrole-2-boronic acid 138900-55-7, 1-(Triisopropylsilyl)pyrrole-3-boronic acid 150401-96-0  
 151169-75-4, 3,4-Dichlorophenylboronic acid 214360-60-8,  
 N-[4-(4,4,5,5-Tetramethyl-1,3,2)dioxaborolan-2-yl]phenyl]acetamide  
 700872-01-1, 4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenol

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of substituted pyrrolo[1,2-b]pyrazoles as mixed lineage kinase modulators)

IT 13602-11-4P, 6-Methylpyridine-2-carboxylic Acid Methyl Ester

20386-22-5P, 1-Aminopyrrolidin-2-one hydrochloride 79289-25-1P  
 79289-48-8P, 1-(Benzhydrylideneamino)pyrrolidin-2-one 141052-31-5P,  
 7-Bromo-4-methylquinoline 476472-31-8P, 2-(7-Bromoquinolin-4-yl)-1-(6-  
 methylpyridin-2-yl)ethanone 476472-35-2P, 2-(7-Bromoquinolin-4-yl)-1-  
 pyridin-2-ylethanone 476473-60-6P, 1-[2-(7-Bromoquinolin-4-yl)-1-(6-  
 methylpyridin-2-yl)ethylideneamino]pyrrolidin-2-one 476473-64-0P,  
 1-[[2-(7-Bromoquinolin-4-yl)-1-(pyridin-2-yl)ethylidene]amino]pyrrolidin-2-  
 one 476473-88-8P, 2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-  
 b]pyrazole-3-carboxylic acid ethyl ester 476473-89-9P,  
 2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-3-  
 carboxylic Acid 476473-90-2P, 3-Bromo-2-(6-methylpyridin-2-yl)-5,6-  
 dihydro-4H-pyrrolo[1,2-b]pyrazole 476474-61-0P,  
 7-Bromo-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-  
 yl]quinoline 476477-23-3P, 7-Bromo-4-[2-(pyridin-2-yl)-5,6-  
 dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 700871-79-0P,  
 [2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-3-yl]boronic acid  
 700871-80-3P, 3-(2-Oxopyrrolidin-1-ylimino)-3-pyridin-2-ylpropionic Acid  
 Ethyl Ester 700871-81-4P, 3-(6-Methylpyridin-2-yl)-3-(2-oxopyrrolidin-1-  
 ylimino)propionic acid ethyl ester 700871-82-5P, 2-(Pyridin-2-yl)-5,6-  
 dihydro-4H-pyrrolo[1,2-b]pyrazole-3-carboxylic Acid Ethyl Ester  
 700871-83-6P, 2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-3-  
 carboxylic Acid 700871-84-7P, 3-Bromo-2-(pyridin-2-yl)-5,6-dihydro-4H-  
 pyrrolo[1,2-b]pyrazole 700871-85-8P, 2-(6-Methylpyridin-2-yl)-5,6-  
 dihydropyrrolo[1,2-b]pyrazole-3-boronic acid 700871-86-9P,  
 Trifluoromethanesulfonic Acid 7-bromoquinolin-4-yl Ester 700871-87-0P,  
 7-Bromo-4-iodoquinoline 700871-88-1P, 4,7-Dibromoquinoline  
 700873-20-7P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-  
 b]pyrazol-3-yl]-7-[4-(4,4,5,5-tetramethyl-1,3,2]dioxaborolan-2-  
 yl)phenyl]quinoline  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of substituted pyrrolo[1,2-b]pyrazoles as mixed lineage kinase  
 modulators)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> d ibib abs hitstr

L5 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:273570 CAPLUS Full-text

DOCUMENT NUMBER: 148:417257

TITLE: Optimization of a Dihydropyrrolopyrazole Series of

Transforming Growth Factor- $\beta$  Type I Receptor

Kinase Domain Inhibitors: Discovery of an Orally

Bioavailable Transforming Growth Factor- $\beta$

Receptor Type I Inhibitor as Antitumor Agent


AUTHOR(S): Li, Hong-yu; McMillen, William T.; Heap, Charles R.;  
 McCann, Denis J.; Yan, Lei; Campbell, Robert M.;  
 Mundla, Sreenivasa R.; King, Chi-Hsin R.; Dierks,  
 Elizabeth A.; Anderson, Bryan D.; Britt, Karen S.;  
 Huss, Karen L.; Voss, Matthew D.; Wang, Yan; Clawson,  
 David K.; Yingling, Jonathan M.; Sawyer, J. Scott

CORPORATE SOURCE: Discovery Chemistry Research and Technology, Drug  
 Disposition Research, Cancer Research, Lead  
 Optimization Biology, and Chemical Product Research  
 and Development, Lilly Research Laboratories, Eli  
 Lilly and Company, Indianapolis, IN, 46285, USA

SOURCE: Journal of Medicinal Chemistry (2008), 51(7),  
 2302-2306

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI



AB In the continuing effort to expand the SAR of the quinoline domain of dihydropyrrolopyrazole series, the authors have discovered a compound (I), which demonstrated the antitumor efficacy with oral bioavailability. This effort also demonstrated that the PK/PD in vivo target inhibition paradigm is an effective approach to assess potential for antitumor efficacy. The dihydropyrrolopyrazole inhibitor I (LY2109761) is representative of a novel series of antitumor agents.


IT 1018352-60-7P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(optimization of a dihydropyrrolopyrazole series of transforming growth factor- $\beta$  type I receptor kinase domain inhibitors and discovery of an orally bioavailable antitumor agent)

RN 1018352-60-7 CAPLUS

CN Quinoline, 7-(2-chloroethoxy)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



IT 476474-15-4P 476474-29-0P 476475-53-3P  
 476475-69-1P 476475-73-7P 476475-75-9P  
 1018352-70-9P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(optimization of a dihydropyrrolopyrazole series of transforming growth factor- $\beta$  type I receptor kinase domain inhibitors and discovery of an orally bioavailable antitumor agent)

RN 476474-15-4 CAPLUS

CN 1-Pentanamine, 5-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-




3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 476474-29-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[(tetrahydro-2-furanyl)methoxy]- (CA INDEX NAME)




RN 476475-53-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(4-methyl-1-piperazinyl)propoxy]- (CA INDEX NAME)




RN 476475-69-1 CAPLUS

CN Ethanamine, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 476475-73-7 CAPLUS

CN Ethanamine, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N-ethyl-N-methyl- (CA INDEX NAME)




RN 476475-75-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (CA INDEX NAME)



RN 1018352-70-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(1-methyl-2-pyrrolidinyl)propoxy]- (CA INDEX NAME)




IT 476474-11-0P 476474-52-9P 476474-60-9P  
476474-62-1P 476475-01-1P 476475-02-2P  
476475-44-2P 1018352-73-2P 1018352-76-5P  
1018353-32-6P 1018353-35-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(optimization of a dihydropyrrolopyrazole series of transforming growth factor- $\beta$  type I receptor kinase domain inhibitors and discovery of an orally bioavailable antitumor agent)


RN 476474-11-0 CAPLUS

CN 7-Quinolinol, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-52-9 CAPLUS

CN Quinoline, 6-bromo-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-60-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-8-fluoro- (CA INDEX NAME)




RN 476474-62-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-(trifluoromethoxy)- (CA INDEX NAME)




RN 476475-01-1 CAPLUS

CN Quinoline, 2-chloro-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-02-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6,8-dimethoxy- (CA INDEX NAME)




RN 476475-44-2 CAPLUS

CN 6-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, methyl ester (CA INDEX NAME)




RN 1018352-73-2 CAPLUS

CN Benzoic acid, 4-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




RN 1018352-76-5 CAPLUS

CN Benzamide, 4-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 1018353-32-6 CAPLUS

CN Benzonitrile, 4-[[4-[[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)



RN 1018353-35-9 CAPLUS

CN Benzamide, 4-[[4-[[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




IT 476475-90-8P 476475-93-1P 476475-95-3P  
476476-79-6P 476476-97-8P 700874-71-1P  
1018352-79-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(optimization of a dihydropyrrolopyrazole series of transforming growth factor- $\beta$  type I receptor kinase domain inhibitors and discovery of an orally bioavailable antitumor agent)


RN 476475-90-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 476475-93-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-(ethylthio)- (CA INDEX NAME)




RN 476475-95-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-methoxy- (CA INDEX NAME)




RN 476476-79-6 CAPLUS

CN Ethanone, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-1-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 476476-97-8 CAPLUS

CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 700874-71-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)



RN 1018352-79-8 CAPLUS

CN Benzenemethanamine, 4-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




IT 1018353-38-2

RL: RCT (Reactant); RACT (Reactant or reagent)

(optimization of a dihydropyrrolopyrazole series of transforming growth factor- $\beta$  type I receptor kinase domain inhibitors and discovery of an orally bioavailable antitumor agent)

RN 1018353-38-2 CAPLUS

CN Benzenecarbothioamide, 4-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)



IT 476473-79-7P 476474-13-2P 476474-40-5P

476476-80-9P 700874-73-3P 700874-74-4P


700874-75-5P 1018352-65-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(optimization of a dihydropyrrolopyrazole series of transforming growth factor- $\beta$  type I receptor kinase domain inhibitors and discovery of an orally bioavailable antitumor agent)


RN 476473-79-7 CAPLUS

CN Quinoline, 7-(3-chloropropoxy)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-13-2 CAPLUS

CN Quinoline, 7-[(5-chloropentyl)oxy]-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-40-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-methoxy- (CA INDEX NAME)



RN 476476-80-9 CAPLUS


CN Acetic acid, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)



RN 700874-73-3 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]- (CA INDEX NAME)






RN 700874-74-4 CAPLUS

CN Ethanol, 2-[[4-[[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




RN 700874-75-5 CAPLUS

CN Ethanol, 2-[[4-[[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-, 1-methanesulfonate (CA INDEX NAME)



RN 1018352-65-2 CAPLUS

CN Acetic acid, 2-[[4-[[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-, ethyl ester (CA INDEX NAME)




REFERENCE COUNT:

24

THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr 1-9

L5 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2008:273570 CAPLUS Full-text  
DOCUMENT NUMBER: 148:417257  
TITLE: Optimization of a Dihydropyrrolopyrazole Series of  
Transforming Growth Factor- $\beta$  Type I Receptor  
Kinase Domain Inhibitors: Discovery of an Orally  
Bioavailable Transforming Growth Factor- $\beta$   
Receptor Type I Inhibitor as Antitumor Agent  
AUTHOR(S): Li, Hong-yu; McMillen, William T.; Heap, Charles R.;  
McCann, Denis J.; Yan, Lei; Campbell, Robert M.;  
Mundla, Sreenivasa R.; King, Chi-Hsin R.; Dierks,  
Elizabeth A.; Anderson, Bryan D.; Britt, Karen S.;  
Huss, Karen L.; Voss, Matthew D.; Wang, Yan; Clawson,  
David K.; Yingling, Jonathan M.; Sawyer, J. Scott  
CORPORATE SOURCE: Discovery Chemistry Research and Technology, Drug  
Disposition Research, Cancer Research, Lead  
Optimization Biology, and Chemical Product Research  
and Development, Lilly Research Laboratories, Eli  
Lilly and Company, Indianapolis, IN, 46285, USA  
SOURCE: Journal of Medicinal Chemistry (2008), 51(7),  
2302-2306  
CODEN: JMCMAR; ISSN: 0022-2623  
PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI




AB In the continuing effort to expand the SAR of the quinoline domain of dihydropyrrolopyrazole series, the authors have discovered a compound (I), which demonstrated the antitumor efficacy with oral bioavailability. This effort also demonstrated that the PK/PD in vivo target inhibition paradigm is an effective approach to assess potential for antitumor efficacy. The dihydropyrrolopyrazole inhibitor I (LY2109761) is representative of a novel series of antitumor agents.

IT 1018352-60-7P  
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(optimization of a dihydropyrrolopyrazole series of transforming growth factor- $\beta$  type I receptor kinase domain inhibitors and discovery of an orally bioavailable antitumor agent)

RN 1018352-60-7 CAPLUS

CN Quinoline, 7-(2-chloroethoxy)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




IT 476474-15-4P 476474-29-0P 476475-53-3P  
476475-69-1P 476475-73-7P 476475-75-9P  
1018352-70-9P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(optimization of a dihydropyrrolopyrazole series of transforming growth factor- $\beta$  type I receptor kinase domain inhibitors and discovery of an orally bioavailable antitumor agent)


RN 476474-15-4 CAPLUS

CN 1-Pentanamine, 5-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 476474-29-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[(tetrahydro-2-furanyl)methoxy]- (CA INDEX NAME)




RN 476475-53-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(4-methyl-1-piperazinyl)propoxy]- (CA INDEX NAME)




RN 476475-69-1 CAPLUS

CN Ethanamine, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 476475-73-7 CAPLUS

CN Ethanamine, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N-ethyl-N-methyl- (CA INDEX NAME)




RN 476475-75-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (CA INDEX NAME)




RN 1018352-70-9 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(1-methyl-2-pyrrolidinyl)propoxy]- (CA INDEX NAME)




IT 476474-11-0P 476474-52-9P 476474-60-9P  
 476474-62-1P 476475-01-1P 476475-02-2P  
 476475-44-2P 1018352-73-2P 1018352-76-5P  
 1018353-32-6P 1018353-35-9P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (optimization of a dihydropyrrolopyrazole series of transforming growth factor- $\beta$  type I receptor kinase domain inhibitors and discovery of an orally bioavailable antitumor agent)  
 RN 476474-11-0 CAPLUS  
 CN 7-Quinolinol, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 476474-52-9 CAPLUS  
 CN Quinoline, 6-bromo-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-60-9 CAPLUS  
 CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-8-fluoro- (CA INDEX NAME)




RN 476474-62-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-(trifluoromethoxy)- (CA INDEX NAME)




RN 476475-01-1 CAPLUS

CN Quinoline, 2-chloro-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-02-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6,8-dimethoxy- (CA INDEX NAME)




RN 476475-44-2 CAPLUS

CN 6-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, methyl ester (CA INDEX NAME)




RN 1018352-73-2 CAPLUS

CN Benzoic acid, 4-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




RN 1018352-76-5 CAPLUS

CN Benzamide, 4-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 1018353-32-6 CAPLUS

CN Benzonitrile, 4-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)



RN 1018353-35-9 CAPLUS

CN Benzamide, 4-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




IT 476475-90-8P 476475-93-1P 476475-95-3P  
476476-79-6P 476476-97-8P 700874-71-1P  
1018352-79-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(optimization of a dihydropyrrolopyrazole series of transforming growth  
factor- $\beta$  type I receptor kinase domain inhibitors and discovery of  
an orally bioavailable antitumor agent)


RN 476475-90-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-  
(1-pyrrolidinyl)- (CA INDEX NAME)




RN 476475-93-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-  
(ethylthio)- (CA INDEX NAME)



RN 476475-95-3 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-  
methoxy- (CA INDEX NAME)






RN 476476-79-6 CAPLUS

CN Ethanone, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-1-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 476476-97-8 CAPLUS

CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 700874-71-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)



RN 1018352-79-8 CAPLUS

CN Benzenemethanamine, 4-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




IT 1018353-38-2

RL: RCT (Reactant); RACT (Reactant or reagent)

(optimization of a dihydropyrrolopyrazole series of transforming growth factor- $\beta$  type I receptor kinase domain inhibitors and discovery of an orally bioavailable antitumor agent)

RN 1018353-38-2 CAPLUS

CN Benzenecarbothioamide, 4-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)



IT 476473-79-7P 476474-13-2P 476474-40-5P

476476-80-9P 700874-73-3P 700874-74-4P


700874-75-5P 1018352-65-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(optimization of a dihydropyrrolopyrazole series of transforming growth factor- $\beta$  type I receptor kinase domain inhibitors and discovery of an orally bioavailable antitumor agent)


RN 476473-79-7 CAPLUS

CN Quinoline, 7-[(3-chloropropoxy)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-13-2 CAPLUS

CN Quinoline, 7-[(5-chloropentyl)oxy]-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-40-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-methoxy- (CA INDEX NAME)




RN 476476-80-9 CAPLUS

CN Acetic acid, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




RN 700874-73-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]- (CA INDEX NAME)



RN 700874-74-4 CAPLUS


CN Ethanol, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)



RN 700874-75-5 CAPLUS


CN Ethanol, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-

7-quinolinyl]oxy]-, 1-methanesulfonate (CA INDEX NAME)



RN 1018352-65-2 CAPLUS

CN Acetic acid, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:675680 CAPLUS Full-text

DOCUMENT NUMBER: 147:64572

TITLE: Control of intraocular pressure using ALK5 modulation agents

INVENTOR(S): Fleenor, Debra L.; Pang, Iok-Hou; Shepard, Allan R.; Hellberg, Mark R.; Clark, Abbot F.; Klimko, Peter G.

PATENT ASSIGNEE(S): Alcon, Inc., Switz.

SOURCE: PCT Int. Appl., 31pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2007070866	A2	20070621	WO 2006-US62151	20061215
WO 2007070866	A3	20080103		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,			

CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

US 20070142376 A1 20070621 US 2006-611312 20061215

PRIORITY APPLN. INFO.: US 2005-751130P P 20051216

AB The invention discloses an ophthalmic pharmaceutical compn. useful in the treatment of glaucoma and control of intraocular pressure comprising an effective amount of a selective modulator of ALK5 receptor activity. The invention also discloses a method for treating glaucoma and controlling intraocular pressure, comprising applying a therapeutically effective amount of a pharmaceutical composition comprising a selective modulator of ALK5 receptor activity to an affected eye of a patient.


IT 737791-20-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(ALK5 modulators for control of intraocular pressure and treatment of glaucoma)

RN 737791-20-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-  
(CA INDEX NAME)



L5 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:173978 CAPLUS Full-text

DOCUMENT NUMBER: 146:229339

TITLE: Preparation of 2-(6-methylpyridin-2-yl)-3-[6-amidoquinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole monohydrate as a transforming growth factor- $\beta$  (TGF- $\beta$ ) inhibitor.

INVENTOR(S): Mundla, Sreenivasa Reddy

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 23pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2007018818	A1	20070215	WO 2006-US25377	20060629
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,			

IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM

CA 2616196 A1 20070215 CA 2006-2616196 20060629  
EP 1910370 A1 20080416 EP 2006-774280 20060629

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,  
BA, HR, MK, RS

PRIORITY APPLN. INFO.:

US 2005-701641P P 20050722  
WO 2006-US25377 W 20060629

AB Title compd. (I) was prepd. I [prepn. from 4-aminobenzonitrile, Me vinyl  
ketone, Me 6-methyl-2-pyridinecarboxylate, and 1- [(diphenylmethylene)amino]-  
2-pyrrolidinone given] inhibited TGF- $\beta$  type I with IC<sub>50</sub> = 56 nM.


IT 924898-09-9P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic  
preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
(Preparation); USES (Uses)

(preparation of methylpyridinylamidoquinolinyl dihydropyrrolopyrazole  
monohydrate as a transforming growth factor- $\beta$  inhibitor)

RN 924898-09-9 CAPLUS

CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-  
pyrrolo[1,2-b]pyrazol-3-yl]-, hydrate (1:1) (CA INDEX NAME)



● H<sub>2</sub>O


IT 700874-72-2

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of methylpyridinylamidoquinolinyl dihydropyrrolopyrazole  
monohydrate as a transforming growth factor- $\beta$  inhibitor)

RN 700874-72-2 CAPLUS

CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-  
pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




IT 924898-13-5F

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of methylpyridinylamidoquinolinyldihydropyrrolopyrazole monohydrate as a transforming growth factor- $\beta$  inhibitor)

RN 924898-13-5 CAPLUS

CN 6-Quinolinecarbonitrile, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:393830 CAPLUS Full-text

DOCUMENT NUMBER: 143:90247

TITLE: Complete Inhibition of Anisomycin and UV Radiation but Not Cytokine Induced JNK and p38 Activation by an Aryl-substituted Dihydropyrrolopyrazole Quinoline and Mixed Lineage Kinase 7 Small Interfering RNA

AUTHOR(S): Wang, Xushan; Mader, Mary M.; Toth, John E.; Yu, Xiaohong; Jin, Najia; Campbell, Robert M.; Smallwood, Jeffrey K.; Christe, Michael E.; Chatterjee, Arindam; Goodson, Theodore, Jr.; Vlahos, Chris J.; Matter, William F.; Bloem, Laura J.

CORPORATE SOURCE: Cardiovascular Discovery Research, Lead Optimization Biology, and Discovery Chemistry Research, Eli Lilly and Company, Indianapolis, IN, 46285, USA

SOURCE: Journal of Biological Chemistry (2005), 280(19), 19298-19305

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Mixed lineage kinase 7 (MLK7) is a mitogen-activated protein kinase kinase kinase (MAPKKK) that activates the pro-apoptotic signaling pathways p38 and JNK. A library of potential kinase inhibitors was screened, and a series of dihydropyrrolopyrazole quinolines was identified as highly potent inhibitors of MLK7 in vitro catalytic activity. Of this series, an aryl-substituted dihydropyrrolopyrazole quinoline (DHP-2) demonstrated an IC<sub>50</sub> of 70 nM for inhibition of pJNK formation in COS-7 cell MLK7/JNK cotransfection assays. In stimulated cells, DHP-2 at 200 nM or MLK7 small interfering RNA completely blocked anisomycin and UV induced but had no effect on interleukin-1 $\beta$  or tumor necrosis factor- $\alpha$ -induced p38 and JNK activation. Addnl., the compound blocked anisomycin and UV-induced apoptosis in COS-7 cells. Heart tissue homogenates from MLK7 transgenic mice treated with DHP-2 at 30 mg/kg had reduced JNK and p38 activation with no apparent effect on ERK activation, demonstrating that this compound can be used to block MLK7-driven MAPK pathway activation in vivo. Taken together, these data demonstrate that MLK7 is the MAPKKK required for modulation of the stress-activated MAPKs downstream of

anisomycin and UV stimulation and that DHP-2 can be used to block MLK7 pathway activation in cells as well as in vivo.

IT 700871-95-1 700871-98-3 700872-64-4  
700872-67-9 700872-74-8 700873-61-4  
700873-31-6 700874-52-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(complete inhibition of anisomycin and UV radiation but not cytokine induced JNK and p38 activation by an aryl-substituted dihydropyrrolopyrazole quinoline and mixed lineage kinase 7 small interfering RNA)


RN 700871-96-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700871-95-0


CMF C26 H20 N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 700871-98-3 CAPLUS


CN Phenol, 2-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700871-97-2

CMF C26 H20 N4 O






CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-04-4 CAPLUS

CN Benzenamine, 2-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700872-03-3


CMF C26 H21 N5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 700872-67-9 CAPLUS

CN Benzoic acid, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 700872-74-8 CAPLUS

CN Benzoic acid, 2-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-73-7


CMF C27 H20 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-01-4 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(2-thienyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700873-00-3


CMF C25 H20 N4 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 700873-31-0 CAPLUS

CN Benzenamine, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-2-fluoro- (CA INDEX NAME)



RN 700874-52-8 CAPLUS

CN Benzamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:467896 CAPLUS Full-text

DOCUMENT NUMBER: 141:23528

TITLE: Preparation of substituted pyrrolo[1,2-b]pyrazoles as

INVENTOR(S): mixed lineage kinase modulators  
 Chatterjee, Arindam; Goodson, Theodore, Jr.; Mader,  
 Mary Margaret; Toth, John Eldon  
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA  
 SOURCE: PCT Int. Appl., 111 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048383	A1	20040610	WO 2003-US35036	20031112
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2506799	A1	20040610	CA 2003-2506799	20031112
AU 2003298611	A1	20040618	AU 2003-298611	20031112
EP 1567528	A1	20050831	EP 2003-796362	20031112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006522735	T	20061005	JP 2004-555371	20031112
US 20080113977	A1	20080515	US 2005-535061	20050512
PRIORITY APPLN. INFO.:			US 2002-428322P	P 20021121
			WO 2003-US35036	W 20031112
OTHER SOURCE(S):		MARPAT 141:23528		
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB Title compds. I [R1 = H, halo, alkyl; R2 = (un)substituted aryl] are prepared  
 For instance, An appropriately substituted 1-[(2,2-  
 disubstituted)ethylideneamino]pyrrolidin-2-one is cyclized to 7-bromo-4-[2-  
 (pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline. This  
 intermediate is coupled to thiophene-2-boronic acid (i-PrOH, K2CO3, (PPh3)4Pd,  
 80°, 5 h) to give II. Certain compds. I have an IC50 ≤ 10,000 nM for mixed  
 lineage kinase 7 (MLK7). I are useful for the treatment of congestive heart  
 disease.

IT 700872-48-6P, 3-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-  
 b]pyrazol-3-yl]quinolin-7-yl]phenyl]propionic Acid trifluoroacetate  
 700872-67-9P, 4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-  
 b]pyrazol-3-yl]quinolin-7-yl]benzoic acid 700874-15-3P,  
 [2-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-  
 yl]quinolin-7-yl]benzoylamino]ethyl]carbamic acid tert-butyl ester  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
 (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of substituted pyrrolo[1,2-b]pyrazoles as mixed lineage kinase  
 modulators)

RN 700872-48-6 CAPLUS  
 CN Benzenepropanoic acid, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 700872-47-5  
 CMF C29 H24 N4 O2




CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 700872-67-9 CAPLUS  
 CN Benzoic acid, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)



RN 700874-15-3 CAPLUS  
 CN Carbamic acid, [2-[[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 700871-92-7F, 7-(4-Methylthiophene-2-yl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline Trifluoroacetate  
 700871-94-9F 700871-96-1F, 7-Phenyl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate  
 700871-98-3F 700872-00-0F 700872-02-2F  
 700872-04-4F 700872-06-6F 700872-10-2F,  
 7-(3-Chlorophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-12-4F,  
 7-(4-Chlorophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-14-6F,  
 7-(3-Nitrophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-16-8F,  
 7-(4-Nitrophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-18-0F  
 700872-20-4F, N-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]methanesulfonamide trifluoroacetate  
 700872-22-6F, 7-(2-Ethoxyphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate  
 700872-24-8F, 7-(3-Ethoxyphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate  
 700872-26-0F, 7-(4-Ethoxyphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate  
 700872-28-2F, 7-(4-Methoxyphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate  
 700872-30-6F, 7-(4-Fluoro-3-methylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate  
 700872-32-8F, 7-(4-Fluoro-2-methylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate  
 700872-34-0F, 7-(4-Bromophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-36-2F  
 , 7-(4-Ethylsulfanylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-38-4F,  
 7-(4-Methylsulfanylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-40-8F,  
 4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzonitrile trifluoroacetate 700872-42-0F  
 700872-44-2F, 1-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]ethanone trifluoroacetate  
 700872-46-4F, 2-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]benzamide trifluoroacetate  
 700872-50-0F, 7-(3,5-Dichlorophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate  
 700872-52-2F, 7-(4-Methoxy-3-methylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate  
 700872-54-4F 700872-56-6F 700872-58-8F  
 700872-60-2F, 7-(2-Nitrophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-62-4F  
 700872-64-6F, 7-(4-(Methanesulfinyl)phenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate  
 700872-66-8F, 7-Benzo[1,3]dioxol-5-yl-4-[2-(pyridin-2-yl)-5,6-

dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate  
 700872-68-0P, 4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoic Acid trifluoroacetate  
 700872-70-4P, 7-(3,5-Bis-trifluoromethylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate  
 700872-72-6P, 3-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoic acid trifluoroacetate  
 700872-74-8P, 2-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoic acid trifluoroacetate  
 700872-76-0P, 7-(4-Isobutylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate  
 700872-78-2P, [4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenoxy]acetic Acid trifluoroacetate  
 700872-80-6P, 7-Benzo[b]thiophene-2-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate  
 700872-82-8P, 7-Benzofuran-2-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-84-0P  
 , 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[thiophene-3-yl]quinoline trifluoroacetate 700872-86-2P,  
 7-Furan-3-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-88-4P,  
 7-(4-Methyl-3-nitrophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-90-8P,  
 7-(4-Cyclohexylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline Trifluoroacetate 700872-92-0P,  
 7-[4-(Benzo[b]thiophene-3-yl)phenyl]-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-93-1P  
 , 7-(3,4-Dichlorophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 700872-94-2P, 4-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoic acid  
 700872-95-3P, 3-[4-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]propionic acid  
 700872-96-4P, 7-(4-Fluorophenyl)-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 700872-97-5P,  
 7-(4-Methoxyphenyl)-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 700872-99-7P, 7-Phenyl-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700873-01-4P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[thiophene-2-yl]quinoline trifluoroacetate 700873-02-5P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(3-nitrophenyl)quinoline 700873-03-6P, 7-(4-Chlorophenyl)-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 700873-05-8P,  
 7-Furan-2-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700873-07-0P 700873-09-2P  
 700873-11-6P 700873-13-8P 700873-15-0P  
 700873-17-2P 700873-19-4P, 7-Cyclohexyl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate  
 700873-22-9P 700873-24-1P, [4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]acetic acid trifluoroacetate 700873-26-3P, 7-(4-(Methanesulfonyl)phenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700873-28-5P 700873-30-9P  
 700873-32-1P 700873-34-3P, 5-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]isophthalic acid trifluoroacetate 700873-36-5P 700873-38-7P,  
 7-(2,2-Dioxo-2,3-dihydro-1H-benzo[c]thiophene-5-yl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate  
 700873-40-1P 700873-42-3P 700873-45-6P,  
 7-(6-Methoxypyridazin-3-yl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-

b]pyrazol-3-yl]quinoline difluoroacetate 700873-47-8P,  
 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-  
 [pyrimidin-2-yl]quinoline difluoroacetate 700873-49-0P,  
 4-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-  
 yl]quinolin-7-yl]phenyl]butyramide trifluoroacetate 700873-51-4P  
 700873-53-6P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-  
 b]pyrazol-3-yl]-7-[pyrimidin-5-yl]quinoline difluoroacetate  
 700873-55-8P 700873-57-0P 700873-59-2P,  
 5-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-  
 7-yl]thiophene-2-sulfonic acid amide trifluoroacetate 700873-61-6P  
 700873-63-8P 700873-64-9P, 4-[4-[2-(Pyridin-2-yl)-5,6-  
 dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzenesulfonamide  
 700873-65-0P, 3-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-  
 b]pyrazol-3-yl]quinolin-7-yl]benzenesulfonamide 700873-66-1P,  
 2-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-  
 7-yl]benzenesulfonamide 700873-68-3P 700873-71-8P  
 700873-73-0P, 7-Pyrazol-1-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-  
 pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700873-75-2P  
 700873-76-3P, 4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-  
 b]pyrazol-3-yl]quinolin-7-yl]piperazine-1-carboxylic acid tert-butyl ester  
 700873-78-5P, 7-Piperidin-1-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-  
 pyrrolo[1,2-b]pyrazol-3-yl]quinoline 700873-80-9P  
 700873-81-0P, 3-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-  
 b]pyrazol-3-yl]quinolin-7-yl]phenyl]propionic acid methyl ester  
 700873-83-2P, 3-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-  
 b]pyrazol-3-yl]quinolin-7-yl]phenyl]propionamide 700873-85-4P  
 700873-88-7P 700873-91-2P 700873-93-4P  
 700873-96-7P 700873-98-9P 700874-01-7P  
 700874-04-0P 700874-07-3P 700874-09-5P,  
 7-[4-(2-Methoxyethoxy)phenyl]-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-  
 pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700874-11-9P  
 , 7-[4-(2-Fluoroethoxy)phenyl]-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-  
 pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700874-14-2P  
 , 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-  
 (2,2,2-trifluoroethoxy)phenyl]quinoline trifluoroacetate  
 700874-17-5P, Piperidin-1-yl[4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-  
 pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]methanone  
 700874-18-6P, [4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-  
 b]pyrazol-3-yl]quinolin-7-yl]phenyl]thiomorpholin-4-ylmethanone  
 700874-20-0P, Morpholin-4-yl[4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-  
 pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]methanone  
 700874-22-2P, N-Carbamoylmethyl-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-  
 4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-23-3P  
 , N-[2-(Isopropylamino)ethyl]-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-  
 pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-24-4P,  
 N-[2-(tert-Butylsulfanyl)ethyl]-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-  
 pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-26-6P,  
 3-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-  
 yl]quinolin-7-yl]benzoylamino]propionic Acid Ethyl Ester  
 700874-28-8P, N-(1,1-Dioxotetrahydrothiophene-3-yl)-4-[4-[2-  
 (pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-  
 yl]benzamide 700874-30-2P, 3-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-  
 4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoylamino]piperidine-1-  
 carboxylic acid tert-butyl ester 700874-32-4P  
 700874-34-6P, N-(2-(Morpholin-4-yl)ethyl)-4-[4-[2-(pyridin-2-yl)-  
 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide  
 700874-36-8P, (1,1-Dioxothiophen-4-yl)[4-[4-[2-(pyridin-2-yl)-  
 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]methanone  
 700874-38-0P 700874-40-4P 700874-42-6P,  
 N,N-Dimethyl-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-



yl]quinolin-7-yl]benzamide 700874-44-8P, 3-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoylamino]propionic acid tert-butyl ester 700874-46-0P, N-Methyl-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-48-2P, N-[2-(Methanesulfonyl)ethyl]-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-50-6P, N-[(Dimethylamino)methylene]-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-52-8P, 4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-55-1P 700874-57-3P 700874-59-5P 700874-61-9P 700874-69-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted pyrrolo[1,2-b]pyrazoles as mixed lineage kinase modulators)


RN 700871-92-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-methyl-2-thienyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700871-91-6


CMF C25 H20 N4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700871-94-9 CAPLUS

CN Acetamide, N-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700871-93-8


CMF C28 H23 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700871-96-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700871-95-0


CMF C26 H20 N4



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 700871-98-3 CAPLUS  
 CN Phenol, 2-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 700871-97-2  
 CMF C26 H20 N4 O



CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 700872-00-0 CAPLUS  
 CN Phenol, 3-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 700871-99-4  
 CMF C26 H20 N4 O



CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 700872-02-2 CAPLUS

CN Phenol, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-01-1


CMF C26 H20 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-04-4 CAPLUS

CN Benzenamine, 2-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700872-03-3


CMF C26 H21 N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-06-6 CAPLUS

CN Benzenamine, 3-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700872-05-5


CMF C26 H21 N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-10-2 CAPLUS

CN Quinoline, 7-(3-chlorophenyl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-09-9


CMF C26 H19 Cl N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-12-4 CAPLUS

CN Quinoline, 7-(4-chlorophenyl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-11-3


CMF C26 H19 Cl N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-14-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(3-nitrophenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-13-5


CMF C26 H19 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-16-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-nitrophenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-15-7


CMF C26 H19 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-18-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(3-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-17-9


CMF C27 H22 N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 700872-20-4 CAPLUS


CN Methanesulfonamide, N-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-19-1

CMF C27 H23 N5 O2 S






CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-22-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(2-ethoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-21-5


CMF C28 H24 N4 O



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 700872-24-8 CAPLUS  
CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(3-ethoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 700872-23-7  
CMF C28 H24 N4 O



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 700872-26-0 CAPLUS  
CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-ethoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 700872-25-9  
CMF C28 H24 N4 O



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 700872-28-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-27-1


CMF C27 H22 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-30-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-fluoro-3-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-29-3


CMF C27 H21 F N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-32-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-fluoro-2-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-31-7


CMF C27 H21 F N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-34-0 CAPLUS

CN Quinoline, 7-(4-bromophenyl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-33-9


CMF C26 H19 Br N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-36-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(ethylthio)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-35-1


CMF C28 H24 N4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 700872-38-4 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-

[4-(methylthio)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-37-3


CMF C27 H22 N4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-40-8 CAPLUS

CN Benzonitrile, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-39-5


CMF C27 H19 N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-42-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(1H-indol-5-yl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700872-41-9


CMF C28 H21 N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-44-2 CAPLUS

CN Ethanone, 1-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-43-1


CMF C28 H22 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-46-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 4'-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-45-3


CMF C33 H25 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 700872-50-0 CAPLUS


CN Quinoline, 7-(3,5-dichlorophenyl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-49-7

CMF C26 H18 Cl2 N4






CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-52-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-methoxy-3-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-51-1


CMF C28 H24 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-54-4 CAPLUS

CN Benzenamine, 5-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-2-methyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700872-53-3


CMF C27 H23 N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-56-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-pyridinyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700872-55-5


CMF C25 H19 N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-58-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(3-pyridinyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700872-57-7


CMF C25 H19 N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-60-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(2-nitrophenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-59-9


CMF C26 H19 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-62-4 CAPLUS

CN Acetamide, N-[3-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-61-3


CMF C28 H23 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-64-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(methylsulfinyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-63-5


CMF C27 H22 N4 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-66-8 CAPLUS

CN Quinoline, 7-(1,3-benzodioxol-5-yl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-65-7


CMF C27 H20 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-68-0 CAPLUS

CN Benzoic acid, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-67-9


CMF C27 H20 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-70-4 CAPLUS

CN Quinoline, 7-[3,5-bis(trifluoromethyl)phenyl]-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-69-1


CMF C28 H18 F6 N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-72-6 CAPLUS

CN Benzoic acid, 3-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-71-5


CMF C27 H20 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-74-8 CAPLUS

CN Benzoic acid, 2-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-73-7


CMF C27 H20 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-76-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(2-methylpropyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-75-9


CMF C30 H28 N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 700872-78-2 CAPLUS




CN Acetic acid, 2-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]phenoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-77-1


CMF C28 H22 N4 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-80-6 CAPLUS

CN Quinoline, 7-benzo[b]thien-2-yl-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-79-3


CMF C28 H20 N4 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 700872-82-8 CAPLUS  
 CN Quinoline, 7-(2-benzofuranyl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 700872-81-7  
 CMF C28 H20 N4 O



CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 700872-84-0 CAPLUS  
 CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(3-thienyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 700872-83-9  
 CMF C24 H18 N4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-86-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(3-furanyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-85-1


CMF C24 H18 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 700872-88-4 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-

(4-methyl-3-nitrophenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-87-3


CMF C27 H21 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-90-8 CAPLUS

CN Quinoline, 7-(4-cyclohexylphenyl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-89-5


CMF C32 H30 N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-92-0 CAPLUS

CN Quinoline, 7-(4-benzo[b]thien-3-ylphenyl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700872-91-9


CMF C34 H24 N4 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 700872-93-1 CAPLUS

CN Quinoline, 7-(3,4-dichlorophenyl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 700872-94-2 CAPLUS

CN Benzoic acid, 4-[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 700872-95-3 CAPLUS

CN Benzenepropanoic acid, 4-[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 700872-96-4 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-fluorophenyl)- (CA INDEX NAME)



RN 700872-97-5 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-methoxyphenyl)- (CA INDEX NAME)



RN 700872-99-7 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CRN 700872-98-6  
CMF C27 H22 N4



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 700873-01-4 CAPLUS  
CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(2-thienyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 700873-00-3  
CMF C25 H20 N4 S




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 700873-02-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(3-nitrophenyl)- (CA INDEX NAME)



RN 700873-03-6 CAPLUS

CN Quinoline, 7-(4-chlorophenyl)-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 700873-05-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(2-furanyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700873-04-7

CMF C24 H18 N4 O




CM 2

CRN 76-05-1



CMF C2 H F3 O2




RN 700873-07-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(2-thiazolyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700873-06-9


CMF C23 H17 N5 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-09-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(2-pyrazinyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700873-08-1


CMF C24 H18 N6



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-11-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(2-pyridinyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700873-10-5


CMF C25 H19 N5



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 700873-13-8 CAPLUS  
 CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(1H-pyrrol-2-yl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)


CM 1

CRN 700873-12-7  
 CMF C24 H19 N5



CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 700873-15-0 CAPLUS  
 CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(1H-indol-2-yl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)


CM 1

CRN 700873-14-9  
 CMF C28 H21 N5



CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 700873-17-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(1H-pyrrol-3-yl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700873-16-1


CMF C24 H19 N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-19-4 CAPLUS

CN Quinoline, 7-cyclohexyl-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700873-18-3


CMF C26 H26 N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-22-9 CAPLUS

CN Ethanol, 2-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-quinolinyl]phenoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700873-21-8


CMF C28 H24 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-24-1 CAPLUS

CN Benzeneacetic acid, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700873-23-0


CMF C28 H22 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-26-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(methylsulfonyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700873-25-2


CMF C27 H22 N4 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 700873-28-5 CAPLUS


CN Benzeneethanamine, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-

b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700873-27-4


CMF C28 H25 N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-30-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-methylphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700873-29-6


CMF C27 H22 N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-32-1 CAPLUS

CN Benzenamine, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-2-fluoro-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700873-31-0


CMF C26 H20 F N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-34-3 CAPLUS

CN 1,3-Benzenedicarboxylic acid, 5-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700873-33-2

CMF C28 H20 N4 O4






CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-36-5 CAPLUS

CN 1,3-Benzenedicarboxylic acid, 5-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 1,3-dimethyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700873-35-4


CMF C30 H24 N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-38-7 CAPLUS

CN Quinoline, 7-(1,3-dihydro-2,2-dioxidobenzo[c]thien-5-yl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700873-37-6


CMF C28 H22 N4 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-40-1 CAPLUS

CN 2-Pyridinecarboxylic acid, 6-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:3)  
(CA INDEX NAME)

CM 1

CRN 700873-39-8


CMF C26 H19 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-42-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(5-fluoro-2-pyridinyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700873-41-2


CMF C25 H18 F N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-45-6 CAPLUS

CN Acetic acid, 2,2-difluoro-, compd. with 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(6-methoxy-3-pyridazinyl)quinoline (1:1) (CA INDEX NAME)

CM 1

CRN 700873-44-5


CMF C25 H20 N6 O



CM 2

CRN 381-73-7

CMF C2 H2 F2 O2




RN 700873-47-8 CAPLUS

CN Acetic acid, 2,2-difluoro-, compd. with 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(2-pyrimidinyl)quinoline (1:1) (CA INDEX NAME)

CM 1

CRN 700873-46-7

CMF C24 H18 N6



CM 2

CRN 381-73-7

CMF C2 H2 F2 O2




RN 700873-49-0 CAPLUS

CN Benzenebutanamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700873-48-9


CMF C30 H27 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-51-4 CAPLUS

CN Acetic acid, 2,2-difluoro-, compd. with 7-(1H-benzimidazol-2-yl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline (1:1) (CA INDEX NAME)

CM 1

CRN 700873-50-3

CMF C27 H20 N6



CM 2

CRN 381-73-7

CMF C2 H2 F2 O2




RN 700873-53-6 CAPLUS

CN Acetic acid, 2,2-difluoro-, compd. with 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(5-pyrimidinyl)quinoline (1:1) (CA INDEX NAME)

CM 1

CRN 700873-52-5


CMF C24 H18 N6



CM 2

CRN 381-73-7

CMF C2 H2 F2 O2




RN 700873-55-8 CAPLUS

CN Benzenamine, 2-chloro-4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700873-54-7


CMF C26 H20 Cl N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-57-0 CAPLUS

CN Phenol, 2-chloro-4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-6-fluoro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700873-56-9


CMF C26 H18 Cl F N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-59-2 CAPLUS

CN 2-Thiophenesulfonamide, 5-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700873-58-1


CMF C24 H19 N5 O2 S2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-61-6 CAPLUS

CN Phenol, 5-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-2,3-difluoro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700873-60-5


CMF C26 H18 F2 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 700873-63-8 CAPLUS

CN 2-Benzothiazolamine, 6-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-




b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 700873-62-7


CMF C27 H20 N6 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 700873-64-9 CAPLUS

CN Benzenesulfonamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 700873-65-0 CAPLUS

CN Benzenesulfonamide, 3-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)



RN 700873-66-1 CAPLUS

CN Benzenesulfonamide, 2-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 700873-68-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(1H-imidazol-1-yl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700873-67-2


CMF C23 H18 N6



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 700873-71-8 CAPLUS  
 CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(1H-1,2,4-triazol-1-yl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)


CM 1

CRN 700873-70-7  
 CMF C22 H17 N7



CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 700873-73-0 CAPLUS  
 CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(1H-pyrazol-1-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 700873-72-9  
 CMF C23 H18 N6



CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 700873-75-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(1H-1,2,3-triazol-1-yl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700873-74-1


CMF C22 H17 N7



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 700873-76-3 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 700873-78-5 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-

(1-piperidinyl)- (CA INDEX NAME)




RN 700873-80-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(1,1-dioxido-4-thiomorpholinyl)- (CA INDEX NAME)




RN 700873-81-0 CAPLUS

CN Benzenepropanoic acid, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, methyl ester (CA INDEX NAME)



RN 700873-83-2 CAPLUS

CN Benzenepropanamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 700873-85-4 CAPLUS

CN Ethanamine, 2-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]phenoxy]-N,N-dimethyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700873-84-3


CMF C30 H29 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-88-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-[2-(4-morpholinyl)ethoxy]phenyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700873-87-6


CMF C32 H31 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-91-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-[2-(1-piperidinyl)ethoxy]phenyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700873-90-1


CMF C33 H33 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-93-4 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700873-92-3


CMF C32 H31 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-96-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-[3-(1-piperidinyloxy)propoxy]phenyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700873-95-6


CMF C34 H35 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 700873-98-9 CAPLUS




CN 1-Propanamine, 3-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]phenoxy]-N,N-dimethyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700873-97-8


CMF C31 H31 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700874-01-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-[3-(4-morpholinyl)propoxy]phenyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700874-00-6


CMF C33 H33 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700874-04-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700874-03-9


CMF C33 H33 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700874-07-3 CAPLUS

CN Acetamide, 2-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]phenoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700874-06-2


CMF C28 H23 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700874-09-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(2-methoxyethoxy)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700874-08-4


CMF C29 H26 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700874-11-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(2-fluoroethoxy)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700874-10-8


CMF C28 H23 F N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700874-14-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(2,2,2-trifluoroethoxy)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 700874-13-1


CMF C28 H21 F3 N4 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 700874-17-5 CAPLUS

CN Methanone, [4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]phenyl]-1-piperidinyl- (CA INDEX NAME)




RN 700874-18-6 CAPLUS

CN Methanone, [4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]phenyl]-4-thiomorpholinyl- (CA INDEX NAME)




RN 700874-20-0 CAPLUS

CN Methanone, [4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]phenyl]-4-morpholinyl- (CA INDEX NAME)




RN 700874-22-2 CAPLUS

CN Benzamide, N-(2-amino-2-oxoethyl)-4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 700874-23-3 CAPLUS

CN Benzamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N-[2-[(1-methylethyl)amino]ethyl]- (CA INDEX NAME)




RN 700874-24-4 CAPLUS

CN Benzamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N-[2-[(1,1-dimethylethyl)thio]ethyl]- (CA INDEX NAME)




RN 700874-26-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]-, ethyl ester (CA INDEX NAME)




RN 700874-28-8 CAPLUS

CN Benzamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N-(tetrahydro-1,1-dioxido-3-thienyl)- (CA INDEX NAME)



RN 700874-30-2 CAPLUS


CN 1-Piperidinecarboxylic acid, 3-[[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 700874-32-4 CAPLUS


CN L-Lysine, N2-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]-N6-[(1,1-dimethylethoxy)carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 700874-34-6 CAPLUS

CN Benzamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 700874-36-8 CAPLUS


CN Methanone, [4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]phenyl](1,1-dioxido-4-thiomorpholinyl)- (CA INDEX NAME)



RN 700874-38-0 CAPLUS

CN D-Cysteine, N-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]-S-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 700874-40-4 CAPLUS

CN L-Glutamic acid, N-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 700874-42-6 CAPLUS

CN Benzamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N,N-dimethyl- (CA INDEX NAME)




RN 700874-44-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 700874-46-0 CAPLUS

CN Benzamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N-methyl- (CA INDEX NAME)




RN 700874-48-2 CAPLUS

CN Benzamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N-[2-(methylsulfonyl)ethyl]- (CA INDEX NAME)




RN 700874-50-6 CAPLUS

CN Benzamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N-[(dimethylamino)methylene]- (CA INDEX NAME)



RN 700874-52-8 CAPLUS

CN Benzamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 700874-55-1 CAPLUS

CN Benzamide, N-(2-aminoethyl)-4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700874-54-0


CMF C29 H26 N6 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 700874-57-3 CAPLUS


CN Benzamide, N-[(1S)-5-amino-1-methylpentyl]-4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 700874-56-2

CMF C33 H34 N6 O


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700874-59-5 CAPLUS  
 CN D-Cysteine, N-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]-S-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700874-58-4

CMF C31 H27 N5 O3 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700874-61-9 CAPLUS  
 CN L-Glutamic acid, N-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700874-60-8

CMF C32 H27 N5 O5


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700874-69-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700874-68-6


CMF C30 H25 N5 O3




CM 2

CRN 76-05-1


CMF C2 H F3 O2




IT 700872-01-1, 4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenol  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of substituted pyrrolo[1,2-b]pyrazoles as mixed lineage kinase modulators)  
 RN 700872-01-1 CAPLUS  
 CN Phenol, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)



IT 476474-61-0P, 7-Bromo-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476477-23-3P, 7-Bromo-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 700873-20-7P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(4,4,5,5-tetramethyl-1,3,2]dioxaborolan-2-yl)phenyl]quinoline  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of substituted pyrrolo[1,2-b]pyrazoles as mixed lineage kinase modulators)  
 RN 476474-61-0 CAPLUS  
 CN Quinoline, 7-bromo-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-23-3 CAPLUS  
 CN Quinoline, 7-bromo-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 700873-20-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:467895 CAPLUS Full-text

DOCUMENT NUMBER: 141:23527

TITLE: Preparation of quinolinyl pyrrolopyrazoles as TGF- $\beta$  signal transduction inhibitors

INVENTOR(S): Beight, Douglas Wade; Sawyer, Jason Scott; Yingling, Jonathan Michael

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048382	A1	20040610	WO 2003-US32747	20031110
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2501322	A1	20040610	CA 2003-2501322	20031110
AU 2003291643	A1	20040618	AU 2003-291643	20031110
BR 2003015337	A	20050816	BR 2003-15337	20031110
EP 1565471	A1	20050824	EP 2003-768531	20031110

EP 1565471 B1 20061004  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
CN 1714090 A 20051228 CN 2003-80103840 20031110  
JP 2006514012 T 20060427 JP 2004-555329 20031110  
AT 341550 T 20061015 AT 2003-768531 20031110  
NZ 538942 A 20070126 NZ 2003-538942 20031110  
ES 2273046 T3 20070501 ES 2003-768531 20031110  
US 20060040983 A1 20060223 US 2005-531237 20050413  
US 7265225 B2 20070904  
ZA 2005003121 A 20060726 ZA 2005-3121 20050418  
MX 2005PA05432 A 20050803 MX 2005-PA5432 20050520  
IN 2005KN00943 A 20060421 IN 2005-KN943 20050520  
NO 2005003045 A 20050621 NO 2005-3045 20050621  
HK 1081948 A1 20070504 HK 2006-102038 20060216  
US 20080027102 A1 20080131 US 2007-782659 20070725  
PRIORITY APPLN. INFO.: US 2002-428893P P 20021122  
WO 2003-US32747 W 20031110  
US 2005-531237 A1 20050413

GI



AB The title compds. I and II, useful in treating cancer in a patient, were prepared E.g., a multi-step synthesis of II, starting from 6-bromo-4-methylquinoline and Me 6-methylpyridine-2-carboxylate (preps. given), was given. The compds. I and II inhibit the TGF- $\beta$  type I receptor kinase domain with IC<sub>50</sub> of <20  $\mu$ M, while exhibiting less toxicity in vivo than structurally related compds. as disclosed in PCT/US02/11884. The pharmaceutical composition comprising the compound II is claimed.


IT 760874-71-1P 760874-72-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of quinolinyl pyrrolopyrazoles as TGF- $\beta$  signal transduction inhibitors)



RN 700874-71-1 CAPLUS  
 CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 700874-72-2 CAPLUS  
 CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



IT 476474-11-0  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of quinolinyl pyrrolopyrazoles as TGF- $\beta$  signal transduction inhibitors)


RN 476474-11-0 CAPLUS  
 CN 7-Quinolinol, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



IT 476474-52-9P 476475-44-2P 700874-73-3P  
 700874-74-4P 700874-75-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of quinolinyl pyrrolopyrazoles as TGF- $\beta$  signal transduction inhibitors)

RN 476474-52-9 CAPLUS  
 CN Quinoline, 6-bromo-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-44-2 CAPLUS

CN 6-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, methyl ester (CA INDEX NAME)




RN 700874-73-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]- (CA INDEX NAME)




RN 700874-74-4 CAPLUS

CN Ethanol, 2-[[4-[[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




RN 700874-75-5 CAPLUS

CN Ethanol, 2-[[4-[[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-, 1-methanesulfonate (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:465519 CAPLUS Full-text  
 DOCUMENT NUMBER: 141:190720  
 TITLE: Novel and potent transforming growth factor beta type I receptor kinase domain inhibitor: 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines  
 AUTHOR(S): Li, Hong-Yu; Wang, Yan; Yan, Lei; Campbell, Robert M.; Anderson, Bryan D.; Wagner, Jill R.; Yingling, Jonathan M.  
 CORPORATE SOURCE: Discovery Chemistry Research, Lilly Corporate Center, A Division of Eli Lilly and Company, Lilly Research Laboratory, Indianapolis, IN, 46285, USA  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(13), 3585-3588  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier Science B.V.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 141:190720  
 GI



AB A novel series of 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines was synthesized and their T $\beta$ R-1 inhibitory, p38 MAPK inhibitory, and T $\beta$ R-1-dependent cellular activity were evaluated. Compound I was found to be a highly potent in the enzyme assay and T $\beta$ R-1-dependent cellular assays. In addition, dimer (II), with a urea linker, shows a similar enzyme and cellular activity despite a bulky substitution.


IT 476477-22-2P 476477-26-6P 476477-37-9P  
476477-39-1P

RL: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 7-amino 4-pyridinyl-dihydropyrrolopyrazolyl-quinolines as potent transforming growth factor beta type I receptor kinase domain inhibitor)


RN 476477-22-2 CAPLUS

CN 7-Quinolinamine, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-26-6 CAPLUS

CN Acetamide, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-2-(dimethylamino)- (CA INDEX NAME)




RN 476477-37-9 CAPLUS

CN Urea, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N'-(2-hydroxyethyl)- (CA INDEX NAME)



RN 476477-39-1 CAPLUS

CN Carbamic acid, [4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2-hydroxyethyl ester (9CI) (CA INDEX NAME)



IT 476477-27-7P 476477-28-8P 476477-29-9P

476477-32-4P 476477-36-8P 476477-38-0P

476477-41-5P 476477-94-8P 476477-95-9P

737765-68-3P


RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);

BIOL (Biological study); PREP (Preparation)

(preparation of 7-amino 4-pyridinyl-dihydropyrrolopyrazolyl-quinolines as potent transforming growth factor beta type I receptor kinase domain inhibitor)


RN 476477-27-7 CAPLUS

CN Propanamide, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-3-(dimethylamino)- (CA INDEX NAME)




RN 476477-28-8 CAPLUS

CN Methanesulfonamide, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476477-29-9 CAPLUS

CN Acetamide, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476477-32-4 CAPLUS

CN Urea, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N'-(2-(dimethylamino)ethyl)- (CA INDEX NAME)




RN 476477-36-8 CAPLUS

CN Urea, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N'-(3-(dimethylamino)propyl)- (CA INDEX NAME)




RN 476477-38-0 CAPLUS

CN Carbamic acid, [4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 476477-41-5 CAPLUS

CN Urea, N,N'-bis[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476477-94-8 CAPLUS

CN 2-Oxazolidinone, 3-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476477-95-9 CAPLUS

CN 2-Imidazolidinone, 1-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)



RN 737765-68-3 CAPLUS

CN Urea, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N'-(2-methoxyethyl)- (CA INDEX NAME)



IT 476477-23-3


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 7-amino 4-pyridinyl-dihydropyrrolopyrazolyl-quinolines as

potent transforming growth factor beta type I receptor kinase domain inhibitor)

RN 476477-23-3 CAPLUS

CN Quinoline, 7-bromo-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




IT 737765-69-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 7-amino 4-pyridinyl-dihydropyrrolopyrazolyl-quinolines as potent transforming growth factor beta type I receptor kinase domain inhibitor)

RN 737765-69-4 CAPLUS

CN 7-Quinolinamine, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(diphenylmethylene)- (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:465518 CAPLUS Full-text

DOCUMENT NUMBER: 141:190719

TITLE: Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor- $\beta$  type I receptor kinase domain

AUTHOR(S): Sawyer, J. Scott; Beight, Douglas W.; Britt, Karen S.; Anderson, Bryan D.; Campbell, Robert M.; Goodson, Theodore; Herron, David K.; Li, Hong-Yu; McMillen, William T.; Mort, Nicholas; Parsons, Stephen; Smith, Edward C. R.; Wagner, Jill R.; Yan, Lei; Zhang, Faming; Yingling, Jonathan M.

CORPORATE SOURCE: Discovery Chemistry Research and Technology, Lilly Corporate Center, The Lilly Research Laboratories, Indianapolis, IN, 46285, USA


SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(13), 3581-3584

CODEN: BMCLE8; ISSN: 0960-894X


PUBLISHER: Elsevier Science B.V.



DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 141:190719  
 GI



I



II


AB We have expanded our previously reported series of pyrazole-based inhibitors of the TGF- $\beta$  type I receptor kinase domain (T $\beta$ R-I) to now include new 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole analogs. Limited examination of the SAR of this new series in both enzyme and cell based in vitro assays has revealed selectivity differences with respect to p38 MAP kinase (p38 MAPK) depending on the nature of the 'warhead' group on the dihydropyrrolopyrazole ring. As with our original pyrazole series, Ph substituents tended to show greater selectivity against p38 MAPK than those comprised of the quinoline-4-yl moiety. We have also achieved co-crystallization and X-ray anal. of compds. I and II, two potent examples of this new series, with the T $\beta$ R-I receptor kinase domain.

IT 737791-20-7P

RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (crystal structure; preparation and activity of aryl- and heteroaryl-substituted dihydropyrrolopyrazoles as inhibitors of the transforming growth factor- $\beta$  type I receptor kinase domain)

RN 737791-20-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-  
 (CA INDEX NAME)



IT 476475-11-3P 476475-12-4P 476475-13-5P

476475-77-1P 476476-39-8P 737791-21-8P


737791-22-9P 737791-23-0P 737791-24-1P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);  
 BIOL (Biological study); PREP (Preparation)

(preparation and activity of aryl- and heteroaryl-substituted dihydropyrrolopyrazoles as inhibitors of the transforming growth factor- $\beta$  type I receptor kinase domain)


RN 476475-11-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-[6-(1-methylethyl)-2-pyridinyl]-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-12-4 CAPLUS

CN Quinoline, 4-[2-(6-ethyl-2-pyridinyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-13-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 476475-77-1 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(ethylthio)- (CA INDEX NAME)



RN 476476-39-8 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-

(ethylsulfonyl)- (CA INDEX NAME)




RN 737791-21-8 CAPLUS

CN Quinoline, 4-[2-(5-fluoro-2-pyridinyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 737791-22-9 CAPLUS

CN Quinoline, 7-chloro-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 737791-23-0 CAPLUS

CN Quinoline, 7-chloro-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 737791-24-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-ethoxy- (CA INDEX NAME)




REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2002:906238 CAPLUS Full-text  
 DOCUMENT NUMBER: 138:4598  
 TITLE: Preparation of substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles as TGF- $\beta$  signal transduction inhibitors  
 INVENTOR(S): Sawyer, Jason Scott; Beight, Douglas Wade; Ciapetti, Paola; Decollo, Todd Vincent; Godfrey, Alexander Glenn; Goodson, Theodore, Jr.; Herron, David Kent; Li, Hong-yu; Liao, Junkai; Mcmillen, William Thomas; Miller, Shawn Christopher; Mort, Nicolas Anthony; Yingling, Jonathan Michael; Smith, Edward C. R.  
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA; et al.  
 SOURCE: PCT Int. Appl., 305 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002094833	A1	20021128	WO 2002-US11884	20020513
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2446820	A1	20021128	CA 2002-2446820	20020513
AU 2002339268	A1	20021203	AU 2002-339268	20020513
AU 2002339268	B2	20070531		
EP 1397364	A1	20040317	EP 2002-744115	20020513
EP 1397364	B1	20070725		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002009939	A	20040330	BR 2002-9939	20020513
CN 1511157	A	20040707	CN 2002-810508	20020513
JP 2004535404	T	20041125	JP 2002-591506	20020513
HU 2004000451	A2	20041228	HU 2004-451	20020513
NZ 528525	A	20051028	NZ 2002-528525	20020513
CN 1951939	A	20070425	CN 2006-10094674	20020513

AT 368041	T	20070815	AT 2002-744115	20020513
ES 2289116	T3	20080201	ES 2002-744115	20020513
IN 2003KN01359	A	20060317	IN 2003-KN1359	20031022
ZA 2003008546	A	20050131	ZA 2003-8546	20031031
US 20040106604	A1	20040603	US 2003-477111	20031106
US 7087626	B2	20060808		
MX 2003PA10630	A	20040309	MX 2003-PA10630	20031119
NO 2003005193	A	20031121	NO 2003-5193	20031121
HK 1064375	A1	20080206	HK 2004-107054	20040915
PRIORITY APPLN. INFO.:			US 2001-293464P	P 20010524
			CN 2002-810508	A3 20020513
			WO 2002-US11884	W 20020513
OTHER SOURCE(S):	MARPAT 138:4598			
GI				



AB Title compds. I [R<sup>1</sup> = Ph, pyridine, pyridine-N-oxide, quinoline, naphthyridine, etc.; R<sup>2</sup> = quinoline, quinoline-N-oxide, naphthalene, pyridine, pyridine-N-oxide, quinazoline, etc.; p = 1-8; R<sup>3</sup> = H, alkyl, alkylhydroxy, hydroxy, dialkylamino, etc.; X = C, O, S] were prepared. For instance, 1-[[2-(6-Bromoquinolin-4-yl)-1-(pyridin-2-yl)ethylidene]aminol]pyrrolidin-2-one (preparation given) was treated with NaH in DMF at 80-85° for 18 h to afford II in 54% yield. Selected compds. of the invention had IC<sub>50</sub> < 20.00 μM for the TGF-β type I receptor.

IT 476477-99-3P, (R)-4-[5-(4-Fluorophenyl)-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476478-00-9P, (S)-4-[5-(4-Fluorophenyl)-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (hetero)aromatic substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles as TGF-β signal transduction inhibitors)

RN 476477-99-3 CAPLUS

CN Quinoline, 4-[(5R)-5-(4-fluorophenyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 476478-00-9 CAPLUS

CN Quinoline, 4-[(5S)-5-(4-fluorophenyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 476473-79-7P, 7-(3-Chloropropoxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476473-92-4P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-carboxylic acid methyl ester 476473-93-5P, 6-[3-(Quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl]pyridine-2-carboxylic acid dihydrochloride 476473-94-6P, 3-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]propionic acid 476474-03-0P, [2-(6-Methylpyridin-2-yl)-3-(quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-6-yl]methanol 476474-11-0P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-ol 476474-25-6P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid 476474-31-4P, 6-Bromo-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476474-37-0P, 4-[5-(4-Fluorophenyl)-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-40-5P, 7-Methoxy-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-41-6P, 7-Benzoyloxy-6-methoxy-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-61-0P, 7-Bromo-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-13-5P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-27-1P, 6-[3-(Quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl]pyridine-2-carboxylic acid methyl ester 476475-29-3P, 3-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-6-yl]acrylic acid methyl ester 476475-43-1P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxylic acid


methyl ester 476475-44-2P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxylic acid methyl ester 476475-52-2P, 3-[[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxylpropylamine 476475-79-3P, 7-Benzylsulfanyl-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476475-80-6P, 3-[[4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]sulfanyl]propan-1-ol 476476-34-3P 476476-47-8P, 3-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]acrylic acid methyl ester 476476-85-4P, N,N-Dimethyl-3-[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]benzamide 476477-22-2P, [4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]amine 476477-39-1P, [4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]carbamic acid 2-hydroxyethyl ester 476477-46-0P, 7-Bromo-4-(4-chloro-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476477-49-3P, 3-(7-Bromoquinolin-4-yl)-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-4-ol 476477-54-2P, N,N-Dimethyl-3-[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]thiobenzamide 476477-69-7P, 3-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]propionic acid methyl ester 476477-81-3P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (2-amino-1,1-dimethylethyl)amide

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of (hetero)aromatic substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles as TGF- $\beta$  signal transduction inhibitors)


RN 476473-79-7 CAPLUS

CN Quinoline, 7-(3-chloropropoxy)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476473-92-4 CAPLUS

CN 7-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, methyl ester (CA INDEX NAME)



RN 476473-93-5 CAPLUS


CN 2-Pyridinecarboxylic acid, 6-[5,6-dihydro-3-(4-quinolinyl)-4H-pyrrolo[1,2-b]pyrazol-2-yl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 476473-94-6 CAPLUS

CN 7-Quinolinepropanoic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-03-0 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole-6-methanol, 5,6-dihydro-2-(6-methyl-2-pyridinyl)-3-(4-quinolinyl)- (CA INDEX NAME)



RN 476474-11-0 CAPLUS


CN 7-Quinolinol, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)






RN 476474-25-6 CAPLUS

CN 7-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-31-4 CAPLUS

CN Quinoline, 6-bromo-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-37-0 CAPLUS

CN Quinoline, 4-[5-(4-fluorophenyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-40-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-methoxy- (CA INDEX NAME)




RN 476474-41-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-methoxy-7-(phenylmethoxy)- (CA INDEX NAME)




RN 476474-61-0 CAPLUS

CN Quinoline, 7-bromo-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-13-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-27-1 CAPLUS

CN 2-Pyridinecarboxylic acid, 6-[5,6-dihydro-3-(4-quinolinyl)-4H-pyrrolo[1,2-b]pyrazol-2-yl]-, methyl ester (CA INDEX NAME)




RN 476475-29-3 CAPLUS

CN 2-Propenoic acid, 3-[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinyl]-, methyl ester (CA INDEX NAME)




RN 476475-43-1 CAPLUS

CN 6-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, methyl ester (CA INDEX NAME)




RN 476475-44-2 CAPLUS

CN 6-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, methyl ester (CA INDEX NAME)




RN 476475-52-2 CAPLUS

CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




RN 476475-79-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[(phenylmethyl)thio]- (CA INDEX NAME)




RN 476475-80-6 CAPLUS

CN 1-Propanol, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]thio]- (CA INDEX NAME)




RN 476476-34-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 1-oxide (CA INDEX NAME)




RN 476476-47-8 CAPLUS

CN 2-Propenoic acid, 3-[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, methyl ester (CA INDEX NAME)




RN 476476-85-4 CAPLUS

CN Benzamide, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 476477-22-2 CAPLUS

CN 7-Quinolinamine, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-39-1 CAPLUS

CN Carbamic acid, [4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2-hydroxyethyl ester (9CI) (CA INDEX NAME)




RN 476477-46-0 CAPLUS


CN Quinoline, 7-bromo-4-[4-chloro-5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-49-3 CAPLUS  
 CN 4H-Pyrrolo[1,2-b]pyrazol-4-ol, 3-(7-bromo-4-quinolinyl)-5,6-dihydro-2-(2-pyridinyl)- (CA INDEX NAME)




RN 476477-64-2 CAPLUS  
 CN Benzenecarbothioamide, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 476477-69-7 CAPLUS  
 CN 7-Quinolinepropanoic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, methyl ester (CA INDEX NAME)



RN 476477-81-3 CAPLUS  
 CN 7-Quinolinecarboxamide, N-(2-amino-1,1-dimethylethyl)-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



IT 476474-51-8P, 4-[5-Methyl-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-52-9P, 6-Bromo-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-53-0P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-trifluoromethylquinoline 476474-60-9P, 8-Fluoro-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-62-1P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-trifluoromethoxyquinoline 476474-63-2P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-trifluoromethylquinoline 476474-64-3P, 7-Methoxy-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-66-5P, [3-(7-Bromoquinolin-4-yl)-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-6-yl]methanol 476474-67-6P, 4-[2-(6-Chloropyridin-2-yl)-5-(4-fluorophenyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-68-7P, 4-[2-(6-Ethoxypyridin-2-yl)-5-(4-fluorophenyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-69-8P, (S)-4-[6-Benzoyloxymethyl-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-chloroquinoline 476474-70-1P, (S)-4-[6-Benzoyloxymethyl-2-(6-chloropyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-71-2P, 4-[2-(6-Methylpyridin-2-yl)-3-(quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-5-yl]benzoic acid ethyl ester 476474-88-1P, 4-[2-(Quinolin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-90-5P, 4-[5-(4-Fluorophenyl)-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-91-6P, 4-(6-Hydroxymethyl-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476474-93-8P, 4-[4-Methyl-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-94-9P, 4-[5-Benzyl-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-96-1P, 4-(5-Phenethyl-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476474-97-2P, 4-[5-Phenyl-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-01-1P, 2-Chloro-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-02-2P, 6,8-Dimethoxy-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-03-3P, 4-[2-(6-Bromopyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-04-4P, 6,8-Dimethoxy-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-10-2P, 4-[2-(6-Propylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-11-3P, 4-[2-(6-Isopropylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-12-4P, 4-[2-(6-Ethylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-18-0P, 4-[2-(4-Chloropyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-21-5P, 4-[5-(3-Methoxyphenyl)-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-25-9P, 6,7-Difluoro-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline

476475-26-0P, 6,7-Dimethoxy-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-35-1P, 6,7-Dichloro-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-37-3P, 6-(4-Fluorophenyl)-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-38-4P, 6-Benzo[1,3]dioxol-5-yl-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-39-5P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-(thiophen-2-yl)quinoline 476475-40-8P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-phenylquinoline 476475-45-3P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid methyl ester 476475-47-5P, Dimethyl [3-[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]propyl]amine 476475-48-6P, [3-[6-Methoxy-4-[2-(pyridin-2-yl)-5,6-dihydropyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propyl]dimethylamine 476475-49-7P, ((Cyclopropyl)methyl) propyl [3-[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxy]propyl]amine 476475-50-0P, Diethyl [3-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propyl]amine 476475-51-1P, Ethyl methyl [3-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propyl]amine 476475-53-3P, 7-[3-(4-Methylpiperazin-1-yl)propoxy]-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476475-54-4P, Benzyl methyl [3-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propyl]amine 476475-55-5P, 7-(3-(Piperidin-1-yl)propoxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476475-56-6P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-7-(3-(pyrrolidin-1-yl)propoxy)quinoline 476475-57-7P, 7-(3-(Azepan-1-yl)propoxy)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-58-8P, 7-(3-(Imidazol-1-yl)propoxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476475-59-9P, 7-(3-(Pyrazol-1-yl)propoxy)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-60-2P, 1'-[3-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propyl][1,4']bipiperidinyl 476475-61-3P, Cyclopropyl 1-methylpiperidin-4-yl [3-[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxy]propyl]amine 476475-62-4P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-7-[3-[1,2,3-triazol-1-yl]propoxy]quinoline 476475-63-5P, Dimethyl [3-[4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propyl]amine 476475-64-6P, Diethyl [3-[4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propyl]amine 476475-65-7P, (Cyclopropylmethyl) propyl [3-[4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propyl]amine 476475-67-9P, Ethyl methyl [3-[4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propyl]amine 476475-69-1P, Dimethyl [2-[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxy]ethyl]amine 476475-71-5P, Diethyl [2-[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxy]ethyl]amine 476475-72-6P, 7-(2-(Piperidin-1-yl)ethoxy)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-73-7P, Ethyl methyl [2-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]ethyl]amine 476475-74-8P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-7-(2-



(pyrrolidin-1-yl)ethoxy)quinoline 476475-75-9P,  
7-[2-(4-Methylpiperazin-1-yl)ethoxy]-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476475-76-0P,  
7-Methylsulfanyl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-77-1P, 7-Ethylsulfanyl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-78-2P,  
6-Methylsulfanyl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-81-7P, Dimethyl  
[2-[[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]sulfanyl]ethyl]amine 476475-82-8P, Dimethyl  
[[6-[3-(quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl]pyridin-2-yl]methyl]amine 476475-83-9P, 7-(2-Propoxyethoxy)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline  
476475-86-2P, 3-[3-[[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxy]propyl]oxazolidin-2-one  
476475-87-3P, 1-[3-[[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxy]propyl]imidazolidin-2-one  
476475-88-4P, 3-[3-[[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxy]propyl]-3H-benzoxazol-2-one  
476475-90-8P, 4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-(pyrrolidin-1-yl)quinoline 476475-91-9P,  
2-Phenylsulfanyl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-92-0P, 2-Morpholin-4-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline  
476475-93-1P, 2-Ethylsulfanyl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-94-2P, Phenyl  
[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-2-yl]amine 476475-95-3P, 2-Methoxy-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-96-4P,  
2-Ethoxy-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-97-5P, 4-[2-(6-Phenylsulfanylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-98-6P,  
Phenyl[6-(3-(quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl)pyridin-2-yl]amine 476475-99-7P, 4-[2-[6-(4-Methoxyphenyl)pyridin-2-yl]-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-00-3P, 4-[2-(6-Phenylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-01-4P,  
4-[2-(6-Morpholin-4-ylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-02-5P, 4-[2-(6-Pyrrolidin-1-ylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-03-6P,  
4-[2-(6-Methoxypyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-04-7P, 7-Benzoyloxy-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline  
476476-05-8P, 2-[3-[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]propyl]isoindole-1,3-dione  
476476-06-9P, 7-(3-Fluoropropoxy)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-07-0P,  
7-(3-Chloropropoxy)-6-methoxy-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-08-1P,  
7-(3-Chloropropoxy)-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-10-5P, N,N-Diethyl-2-[[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]acetamide 476476-11-6P, (R)-7-[2-(2-Methylpyrrolidin-2-yl)ethoxy]-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-14-9P, 7-(1-Methylpiperidin-3-ylmethoxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476476-15-0P, 7-((3-Dimethylamino-2-methylpropyl)oxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476476-16-1P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-propoxyquinoline 476476-17-2P,

4-[6-Benzylloxymethyl-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-18-3P, [[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]acetic acid methyl ester 476476-19-4P, 7-Isopropoxy-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-20-7P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(morpholin-4-yl)propoxy]quinoline 476476-23-0P, 2-[4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]acetamide 476476-24-1P, 7-(5-Phenyl[1,2,4]oxadiazol-3-ylmethoxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476476-25-2P, 7-(2,2-Difluorobenzo[1,3]dioxol-5-ylmethoxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476476-26-3P, (S)-7-[2-(1-Methylpyrrolidin-2-yl)ethoxy]-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476476-27-4P, 5-[[[4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxy]methyl]pyrrolidin-2-one 476476-28-5P, 4-(6-Phenoxymethyl-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476476-29-6P, 4-(6-Methylene-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476476-31-0P, 7-((1-Methylpiperidin-2-yl)methoxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline hydrochloride 476476-32-1P 476476-33-2P, 7-[2-(1-Methylpyrrolidin-2-yl)ethoxy]-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline hydrochloride 476476-35-4P, 7-Methanesulfonyl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-38-7P, 6-Methanesulfonyl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-39-8P, 7-Ethanesulfonyl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-40-1P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(pyrimidine-2-sulfonyl)propoxy]quinoline 476476-41-2P, 7-[3-((1-Methyl-1H-imidazol-2-yl)sulfonyl)propoxy]-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-42-3P, 7-[3-(4-Chlorobenzenesulfonyl)propoxy]-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-43-4P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-7-[3-(((pyridin-2-yl)methane)sulfonyl)propoxy]quinoline 476476-44-5P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-7-[3-(((pyridin-2-yl)methane)sulfinyl)propoxy]quinoline 476476-46-7P 476476-48-9P, 3-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]-1-(piperidin-1-yl)propenone 476476-49-0P, N,N-Dimethyl-3-[4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]acrylamide 476476-50-3P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-vinylquinoline 476476-51-4P, 4-[2-(6-Benzylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-52-5P, 7-Benzyl-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-53-6P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid ethyl ester 476476-54-7P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxylic acid 476476-55-8P, 3-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]acrylic acid 476476-56-9P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-carboxylic acid cyclopentylamide 476476-57-0P, 4-[2-(6-Methylpyridin-2-yl)-3-(quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-5-yl]benzoic acid 476476-58-1P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (2-(morpholin-4-yl)ethyl)amide 476476-59-2P,

4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid [2-(1H-imidazol-4-yl)ethyl]amide 476476-60-5P,  
 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (2-methylaminoethyl)amide 476476-61-6P,  
 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (3-methylaminopropyl)amide 476476-62-7P,  
 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (2-dimethylaminoethyl)amide 476476-63-8P,  
 (4-Methylpiperazin-1-yl)[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]methanone 476476-64-9P,  
 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid cyclobutylamide 476476-65-0P,  
 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid cyclopropylamide 476476-66-1P,  
 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (1-ethylpropyl)amide 476476-67-2P,  
 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid ethylamide 476476-68-3P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid isobutylamide 476476-69-4P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid tert-butylamide 476476-70-7P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid isopropylamide 476476-71-8P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid propylamide 476476-72-9P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (2-methylbutyl)amide 476476-73-0P 476476-74-1P 476476-75-2P 476476-76-3P 476476-77-4P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (pyridin-4-ylmethyl)amide 476476-78-5P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (pyridin-3-ylmethyl)amide 476476-79-6P, 1-(4-Methylpiperazin-1-yl)-2-[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]ethanone 476476-81-0P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (pyridin-2-ylmethyl)amide 476476-82-1P, 6-(3-(Quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl)pyridine-2-carboxylic acid amide 476476-83-2P, N-(2-Dimethylaminoethyl)-2-[[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]acetamide 476476-84-3P, N-(2-Dimethylaminoethyl)-N-methyl-2-[[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]acetamide 476476-85-5P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid amide 476476-89-8P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid ((2-dimethylaminoethyl)methyl)amide 476476-91-2P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid [[3-(dimethylamino)propyl]methyl]amide 476476-93-4P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid dimethylamide 476476-94-5P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid methylamide 476476-95-6P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid N-(pyridin-2-yl)amide 476476-96-7P, N-(2,2-Dimethylaminoethyl)-N-methyl-3-[4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]propionamide 476476-97-3P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxylic acid (2-dimethylaminoethyl)amide 476476-98-9


P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxylic acid (3-dimethylaminopropyl)amide 476476-99-0P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxylic acid (2-(morpholin-4-yl)ethyl)amide 476477-00-6P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (2-(piperidinyl)ethyl)amide 476477-01-7P, N-(2-Dimethylaminoethyl)-3-[4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]propionamide 476477-02-8P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (3-(morpholin-4-yl)propyl)amide 476477-03-9P, 3-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]propionamide 476477-04-0P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxylic acid (2-dimethylaminoethyl)amide 476477-05-1P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxylic acid [2-(morpholin-4-yl)ethyl]amide 476477-06-2P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxylic acid 476477-07-3P 476477-08-4P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxylic acid amide 476477-09-5P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxylic acid (3-methylaminopropyl)amide 476477-10-8P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxylic acid (2-hydroxyethyl)amide 476477-11-9P 476477-12-0P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-carboxylic acid hydroxyamide 476477-13-1P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-carboxylic acid (2-aminoethyl)amide 476477-14-2P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-carboxylic acid (2-hydroxyethyl)amide 476477-15-3P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid amide 476477-16-4P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid ((2-dimethylaminoethyl)methyl)amide 476477-17-5P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-sulfonic acid amide 476477-18-6P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-sulfonic acid methylamide 476477-19-7P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-sulfonic acid dimethylamide 476477-20-0P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-sulfonic acid [3-(dimethylamino)propyl]amide 476477-21-1P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-sulfonic acid diethylamide 476477-24-4P 476477-25-5P 476477-26-6P, 2-(Dimethylamino)-N-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]acetamide 476477-27-7P, 3-Dimethylamino-N-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]propionamide 476477-28-8P, N-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]methanesulfonamide 476477-29-9P, N-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]acetamide 476477-31-3P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-carboxylic acid [2-dimethylamino-1-methylethyl]amide 476477-32-4P, N-(2-Dimethylaminoethyl)-N'-[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]urea 476477-33-5P, N-[3-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yloxy]propyl]methanesulfonamide 476477-34-6P, 1-Methyl-1H-imidazole-4-sulfonic acid [3-[4-(2-(pyridin-2-yl)-5,6-dihydro-

4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yloxy]propyl]amide  
 476477-35-7P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-  
 pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid  
 (2-dimethylamino-1-methylethyl)amide 476477-36-8P,  
 N-(3-Dimethylaminopropyl)-N'-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-  
 pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]urea 476477-37-9P,  
 N-(2-Hydroxyethyl)-N'-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-  
 b]pyrazol-3-yl]quinolin-7-yl]urea 476477-38-0P,  
 [4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-  
 yl]carbamic acid methyl ester 476477-40-4P, [4-[2-(Pyridin-2-yl)-  
 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]carbamic acid  
 2-methoxyethyl ester 476477-41-5P, N,N'-Bis[4-(2-(pyridin-2-yl)-  
 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]urea  
 476477-42-6P, Dimethylcarbamic acid 4-[2-(pyridin-2-yl)-5,6-  
 dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl ester  
 476477-43-7P, 7-Bromo-2-isopropyl-4-(2-(pyridin-2-yl)-5,6-dihydro-  
 4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476477-44-8P,  
 2-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-  
 yl]quinolin-6-yl]propan-2-ol 476477-45-9P, 7-((3-  
 Chloropropyl)sulfanyl)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-  
 b]pyrazol-3-yl]quinoline 476477-47-1P, 8-Chloro-4-(2-(pyridin-2-  
 yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-ol  
 476477-48-2P, 8-Bromo-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-  
 pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-ol 476477-50-6P,  
 7-Bromo-4-[4-methoxy-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-  
 3-yl]quinoline 476477-51-7P, [3-(7-Bromoquinolin-4-yl)-2-  
 (pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-4-yl]methylamine  
 476477-53-9P, 3-(7-Bromoquinolin-4-yl)-2-(pyridin-2-yl)-5,6-  
 dihydropyrrolo[1,2-b]pyrazol-4-one 476477-54-0P,  
 3-[4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-  
 7-yloxy]benzonitrile 476477-56-2P, 3-[4-(2-(Pyridin-2-yl)-5,6-  
 dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yloxy]benzamide  
 476477-58-4P, 7-(6-Methylpyridazin-3-yloxy)-4-[2-(pyridin-2-yl)-  
 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476477-60-8P  
 , 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(4-  
 (pyrimidin-2-yl)piperazin-1-yl)butoxy]quinoline 476477-65-3P,  
 Dimethyl[3-[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-  
 yl]quinolin-7-yloxy]benzyl]amine 476477-66-4P,  
 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-  
 quinolin-2-one 476477-67-5P, 4-[2-(6-Methylpyridin-2-yl)-5,6-  
 dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-ol  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of (hetero)aromatic substituted 5,6-dihydro-4H-pyrrolo[1,2-  
 b]pyrazoles as TGF- $\beta$  signal transduction inhibitors)


RN 476474-51-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-5-methyl-2-(2-pyridinyl)-4H-pyrrolo[1,2-  
 b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-52-9 CAPLUS

CN Quinoline, 6-bromo-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-53-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-(trifluoromethyl)- (CA INDEX NAME)




RN 476474-60-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-8-fluoro- (CA INDEX NAME)




RN 476474-62-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-(trifluoromethoxy)- (CA INDEX NAME)




RN 476474-63-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(trifluoromethyl)- (CA INDEX NAME)




RN 476474-64-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-methoxy- (CA INDEX NAME)




RN 476474-66-5 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole-6-methanol, 3-(7-bromo-4-quinolinyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 476474-67-6 CAPLUS

CN Quinoline, 4-[2-(6-chloro-2-pyridinyl)-5-(4-fluorophenyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-68-7 CAPLUS  
 CN Quinoline, 4-[2-(6-ethoxy-2-pyridinyl)-5-(4-fluorophenyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-69-8 CAPLUS  
 CN Quinoline, 7-chloro-4-[(6S)-5,6-dihydro-2-(6-methyl-2-pyridinyl)-6-[(phenylmethoxy)methyl]-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 476474-70-1 CAPLUS  
 CN Quinoline, 4-[(6S)-2-(6-chloro-2-pyridinyl)-5,6-dihydro-6-[(phenylmethoxy)methyl]-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 476474-71-2 CAPLUS  
 CN Benzoic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-3-(4-quinolinyl)-4H-pyrrolo[1,2-b]pyrazol-5-yl]-, ethyl ester (CA INDEX NAME)






RN 476474-88-1 CAPLUS

CN Quinoline, 2-[5,6-dihydro-3-(4-quinolinyl)-4H-pyrrolo[1,2-b]pyrazol-2-yl]-  
(CA INDEX NAME)




RN 476474-90-5 CAPLUS

CN Quinoline, 4-[5-(4-fluorophenyl)-5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-  
(CA INDEX NAME)




RN 476474-91-6 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole-6-methanol, 5,6-dihydro-2-(2-pyridinyl)-3-(4-quinolinyl)-  
(CA INDEX NAME)




RN 476474-93-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-4-methyl-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-  
(CA INDEX NAME)




RN 476474-94-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-5-(phenylmethyl)-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-96-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-5-(2-phenylethyl)-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-97-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-5-phenyl-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-01-1 CAPLUS

CN Quinoline, 2-chloro-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-02-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6,8-dimethoxy- (CA INDEX NAME)




RN 476475-03-3 CAPLUS

CN Quinoline, 4-[2-(6-bromo-2-pyridinyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6,8-dimethoxy- (CA INDEX NAME)




RN 476475-04-4 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6,8-dimethoxy- (CA INDEX NAME)




RN 476475-10-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-propyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6,8-dimethoxy- (CA INDEX NAME)




RN 476475-11-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-[6-(1-methylethyl)-2-pyridinyl]-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-12-4 CAPLUS

CN Quinoline, 4-[2-(6-ethyl-2-pyridinyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-18-0 CAPLUS

CN Quinoline, 4-[2-(4-chloro-2-pyridinyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-21-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-5-(3-methoxyphenyl)-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-25-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6,7-difluoro- (CA INDEX NAME)




RN 476475-26-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6,7-dimethoxy- (CA INDEX NAME)




RN 476475-35-1 CAPLUS

CN Quinoline, 6,7-dichloro-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-37-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-(4-fluorophenyl)- (CA INDEX NAME)




RN 476475-38-4 CAPLUS

CN Quinoline, 6-(1,3-benzodioxol-5-yl)-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-39-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-(2-thienyl)- (CA INDEX NAME)




RN 476475-40-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-phenyl- (CA INDEX NAME)




RN 476475-45-3 CAPLUS

CN 7-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, methyl ester (CA INDEX NAME)




RN 476475-47-5 CAPLUS

CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 476475-48-6 CAPLUS

CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-methoxy-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 476475-49-7 CAPLUS

CN Cyclopropanemethanamine, N-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]-N-propyl- (CA INDEX NAME)




RN 476475-50-0 CAPLUS

CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-diethyl- (CA INDEX NAME)




RN 476475-51-1 CAPLUS

CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N-ethyl-N-methyl- (CA INDEX NAME)




RN 476475-53-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(4-methyl-1-piperazinyl)propoxy]- (CA INDEX NAME)



RN 476475-54-4 CAPLUS


CN Benzenemethanamine, N-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]-N-methyl- (CA INDEX NAME)



RN 476475-55-5 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)






RN 476475-56-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)




RN 476475-57-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(hexahydro-1H-azepin-1-yl)propoxy]- (CA INDEX NAME)




RN 476475-58-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(1H-imidazol-1-yl)propoxy]- (CA INDEX NAME)




RN 476475-59-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(1H-pyrazol-1-yl)propoxy]- (CA INDEX NAME)




RN 476475-60-2 CAPLUS

CN Quinoline, 7-(3-[1,4'-bipiperidin]-1'-ylpropoxy)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-61-3 CAPLUS

CN 4-Piperidinamine, N-cyclopropyl-N-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]-1-methyl- (CA INDEX NAME)



RN 476475-62-4 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(1H-1,2,3-triazol-1-yl)propoxy]- (CA INDEX NAME)



RN 476475-63-5 CAPLUS


CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-

b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 476475-64-6 CAPLUS

CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-diethyl- (CA INDEX NAME)




RN 476475-65-7 CAPLUS

CN Cyclopropanemethanamine, N-[3-[[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]-N-propyl- (CA INDEX NAME)




RN 476475-67-9 CAPLUS

CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N-ethyl-N-methyl- (CA INDEX NAME)




RN 476475-69-1 CAPLUS

CN Ethanamine, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 476475-71-5 CAPLUS

CN Ethanamine, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-diethyl- (CA INDEX NAME)




RN 476475-72-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)



RN 476475-73-7 CAPLUS


CN Ethanamine, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N-ethyl-N-methyl- (CA INDEX NAME)



RN 476475-74-8 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-

[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)




RN 476475-75-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (CA INDEX NAME)




RN 476475-76-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(methylthio)- (CA INDEX NAME)




RN 476475-77-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(ethylthio)- (CA INDEX NAME)




RN 476475-78-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-(methylthio)- (CA INDEX NAME)




RN 476475-81-7 CAPLUS

CN Ethanamine, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]thio]-N,N-dimethyl- (CA INDEX NAME)




RN 476475-82-8 CAPLUS

CN 2-Pyridinemethanamine, 6-[5,6-dihydro-3-(4-quinolinyl)-4H-pyrrolo[1,2-b]pyrazol-2-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 476475-83-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(2-propoxyethoxy)- (CA INDEX NAME)




RN 476475-86-2 CAPLUS

CN 2-Oxazolidinone, 3-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]- (CA INDEX NAME)




RN 476475-87-3 CAPLUS

CN 2-Imidazolidinone, 1-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]- (CA INDEX NAME)




RN 476475-88-4 CAPLUS

CN 2(3H)-Benzoxazolone, 3-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]- (CA INDEX NAME)




RN 476475-90-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 476475-91-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-(phenylthio)- (CA INDEX NAME)




RN 476475-92-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-(4-morpholinyl)- (CA INDEX NAME)




RN 476475-93-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-(ethylthio)- (CA INDEX NAME)



RN 476475-94-2 CAPLUS


CN 2-Quinolinamine, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-phenyl- (CA INDEX NAME)



RN 476475-95-3 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-methoxy- (CA INDEX NAME)






RN 476475-96-4 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-ethoxy- (CA INDEX NAME)




RN 476475-97-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-[6-(phenylthio)-2-pyridinyl]-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-98-6 CAPLUS

CN 2-Pyridinamine, 6-[5,6-dihydro-3-(4-quinolinyl)-4H-pyrrolo[1,2-b]pyrazol-2-yl]-N-phenyl- (CA INDEX NAME)




RN 476475-99-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-[6-(4-methoxyphenyl)-2-pyridinyl]-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-00-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-phenyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-01-4 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-[6-(4-morpholinyl)-2-pyridinyl]-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-02-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-[6-(1-pyrrolidinyl)-2-pyridinyl]-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-03-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methoxy-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-04-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(phenylmethoxy)- (CA INDEX NAME)



RN 476476-05-8 CAPLUS


CN 1H-Isoindole-1,3(2H)-dione, 2-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]- (CA INDEX NAME)



RN 476476-06-9 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-

(3-fluoropropoxy)- (CA INDEX NAME)




RN 476476-07-0 CAPLUS

CN Quinoline, 7-(3-chloropropoxy)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-methoxy- (CA INDEX NAME)




RN 476476-08-1 CAPLUS

CN Quinoline, 7-(3-chloropropoxy)-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-methoxy- (CA INDEX NAME)



RN 476476-10-5 CAPLUS


CN Acetamide, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-diethyl- (CA INDEX NAME)



RN 476476-11-6 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-[(2R)-2-methyl-2-pyrrolidinyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 476476-14-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[(1-methyl-3-piperidinyl)methoxy]- (CA INDEX NAME)




RN 476476-15-0 CAPLUS

CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N,2-trimethyl- (CA INDEX NAME)




RN 476476-16-1 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-propoxy- (CA INDEX NAME)




RN 476476-17-2 CAPLUS  
 CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-6-  
 [(phenylmethoxy)methyl]-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-18-3 CAPLUS  
 CN Acetic acid, 2-[[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-  
 b]pyrazol-3-yl]-7-quinolinyl]oxy]-, methyl ester (CA INDEX NAME)



RN 476476-19-4 CAPLUS  
 CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-  
 b]pyrazol-3-yl]-7-(1-methylethoxy)- (CA INDEX NAME)




RN 476476-20-7 CAPLUS  
 CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-  
 b]pyrazol-3-yl]-7-[3-(4-morpholinyl)propoxy]- (CA INDEX NAME)




RN 476476-23-0 CAPLUS

CN Acetamide, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




RN 476476-24-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[(5-phenyl-1,2,4-oxadiazol-3-yl)methoxy]- (CA INDEX NAME)



RN 476476-25-2 CAPLUS


CN Quinoline, 7-[(2,2-difluoro-1,3-benzodioxol-5-yl)methoxy]-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 476476-26-3 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-[(2S)-1-methyl-2-pyrrolidinyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 476476-27-4 CAPLUS

CN 2-Pyrrolidinone, 5-[[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]methyl]- (CA INDEX NAME)




RN 476476-28-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-6-(phoxymethyl)-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 476476-29-6 CAPLUS


CN Quinoline, 4-[5,6-dihydro-6-methylene-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 476476-31-0 CAPLUS




CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-  
[(1-methyl-2-piperidinyl)methoxy]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 476476-32-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-1-oxido-2-pyridinyl)-4H-pyrrolo[1,2-  
b]pyrazol-3-yl]-, 1-oxide (CA INDEX NAME)



RN 476476-33-2 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-  
[2-(1-methyl-2-pyrrolidinyl)ethoxy]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 476476-35-4 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-  
(methylsulfonyl)- (CA INDEX NAME)




RN 476476-38-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-(methylsulfonyl)- (CA INDEX NAME)




RN 476476-39-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(ethylsulfonyl)- (CA INDEX NAME)




RN 476476-40-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(2-pyrimidinylsulfonyl)propoxy]- (CA INDEX NAME)




RN 476476-41-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-[(1-methyl-1H-imidazol-2-yl)sulfonyl]propoxy]- (CA INDEX NAME)




RN 476476-42-3 CAPLUS

CN Quinoline, 7-[3-[(4-chlorophenyl)sulfonyl]propoxy]-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-43-4 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-[(2-pyridinylmethyl)sulfonyl]propoxy]- (CA INDEX NAME)



RN 476476-44-5 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-[(2-pyridinylmethyl)sulfonyl]propoxy]- (CA INDEX NAME)



RN 476476-46-7 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-,

1-oxide (CA INDEX NAME)




RN 476476-48-9 CAPLUS

CN 2-Propen-1-one, 3-[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-1-(1-piperidinyl)- (CA INDEX NAME)




RN 476476-49-0 CAPLUS

CN 2-Propenamide, 3-[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N,N-dimethyl- (CA INDEX NAME)




RN 476476-50-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-ethenyl- (CA INDEX NAME)




RN 476476-51-4 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-[6-(phenylmethyl)-2-pyridinyl]-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-52-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(phenylmethyl)- (CA INDEX NAME)




RN 476476-53-6 CAPLUS

CN 7-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, ethyl ester (CA INDEX NAME)




RN 476476-54-7 CAPLUS

CN 6-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-55-8 CAPLUS

CN 2-Propenoic acid, 3-[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476476-56-9 CAPLUS

CN 7-Quinolinecarboxamide, N-cyclopentyl-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-57-0 CAPLUS

CN Benzoic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-3-(4-quinolinyl)-4H-pyrrolo[1,2-b]pyrazol-5-yl]- (CA INDEX NAME)




RN 476476-58-1 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 476476-59-2 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(1H-imidazol-5-yl)ethyl]- (CA INDEX NAME)




RN 476476-60-5 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(methylamino)ethyl]- (CA INDEX NAME)




RN 476476-61-6 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[3-(methylamino)propyl]- (CA INDEX NAME)




RN 476476-62-7 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 476476-63-8 CAPLUS

CN Methanone, [4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 476476-64-9 CAPLUS

CN 7-Quinolinecarboxamide, N-cyclobutyl-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 476476-65-0 CAPLUS


CN 7-Quinolinecarboxamide, N-cyclopropyl-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 476476-66-1 CAPLUS


CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(1-ethylpropyl)- (CA INDEX NAME)






RN 476476-67-2 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-ethyl- (CA INDEX NAME)




RN 476476-68-3 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 476476-69-4 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 476476-70-7 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(1-methylethyl)- (CA INDEX NAME)




RN 476476-71-8 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-propyl- (CA INDEX NAME)



RN 476476-72-9 CAPLUS


CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(2-methylbutyl)- (CA INDEX NAME)



RN 476476-73-0 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[(2S)-2-methylbutyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 476476-74-1 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[(1S)-1-methylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 476476-75-2 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[(1R)-1-methylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 476476-76-3 CAPLUS


CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[(1R)-1,2-dimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 476476-77-4 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 476476-78-5 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 476476-79-6 CAPLUS

CN Ethanone, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-1-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 476476-81-0 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 476476-82-1 CAPLUS

CN 2-Pyridinecarboxamide, 6-[5,6-dihydro-3-(4-quinolinyl)-4H-pyrrolo[1,2-b]pyrazol-2-yl]- (CA INDEX NAME)




RN 476476-83-2 CAPLUS

CN Acetamide, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 476476-84-3 CAPLUS

CN Acetamide, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N-[2-(dimethylamino)ethyl]-N-methyl- (CA INDEX NAME)




RN 476476-86-5 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-89-8 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[3-(dimethylamino)propyl]- (CA INDEX NAME)




RN 476476-91-2 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[4-(dimethylamino)butyl]- (CA INDEX NAME)




RN 476476-93-4 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 476476-94-5 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-methyl- (CA INDEX NAME)




RN 476476-95-6 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-2-pyridinyl- (CA INDEX NAME)




RN 476476-96-7 CAPLUS


CN 7-Quinolinepropanamide, N-[2,2-bis(methylamino)ethyl]-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-methyl- (CA INDEX NAME)




RN 476476-97-8 CAPLUS  
 CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 476476-98-9 CAPLUS  
 CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[3-(dimethylamino)propyl]- (CA INDEX NAME)



RN 476476-99-0 CAPLUS  
 CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 476477-00-6 CAPLUS  
 CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)







RN 476477-01-7 CAPLUS  
 CN 7-Quinolinepropanamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 476477-02-8 CAPLUS  
 CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)



RN 476477-03-9 CAPLUS  
 CN 7-Quinolinepropanamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-04-0 CAPLUS  
 CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 476477-05-1 CAPLUS

CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 476477-06-2 CAPLUS

CN 6-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-07-3 CAPLUS

CN 6-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, hydrazide (CA INDEX NAME)




RN 476477-08-4 CAPLUS

CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-09-5 CAPLUS

CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[3-(methylamino)propyl]- (CA INDEX NAME)




RN 476477-10-8 CAPLUS

CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 476477-11-9 CAPLUS

CN 7-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, hydrazide (CA INDEX NAME)




RN 476477-12-0 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-hydroxy- (CA INDEX NAME)




RN 476477-13-1 CAPLUS

CN 7-Quinolinecarboxamide, N-(2-aminoethyl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-14-2 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 476477-15-3 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 476477-16-4 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[3-(dimethylamino)propyl]- (CA INDEX NAME)




RN 476477-17-5 CAPLUS

CN 7-Quinolinesulfonamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-18-6 CAPLUS

CN 7-Quinolinesulfonamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-methyl- (CA INDEX NAME)




RN 476477-19-7 CAPLUS

CN 7-Quinolinesulfonamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 476477-20-0 CAPLUS

CN 7-Quinolinesulfonamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[3-(dimethylamino)propyl]- (CA INDEX NAME)




RN 476477-21-1 CAPLUS

CN 7-Quinolinesulfonamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N,N-diethyl- (CA INDEX NAME)




RN 476477-24-4 CAPLUS

CN 7-Quinolinesulfonamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(1-piperidiny)ethyl]- (CA INDEX NAME)




RN 476477-25-5 CAPLUS

CN 7-Quinolinesulfonamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 476477-26-6 CAPLUS

CN Acetamide, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-2-(dimethylamino)- (CA INDEX NAME)




RN 476477-27-7 CAPLUS

CN Propanamide, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-3-(dimethylamino)- (CA INDEX NAME)




RN 476477-28-8 CAPLUS

CN Methanesulfonamide, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476477-29-9 CAPLUS

CN Acetamide, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476477-31-3 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(dimethylamino)-1-methylethyl]- (CA INDEX NAME)




RN 476477-32-4 CAPLUS

CN Urea, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N'-[2-(dimethylamino)ethyl]- (CA INDEX NAME)



RN 476477-33-5 CAPLUS


CN Methanesulfonamide, N-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]- (CA INDEX NAME)



RN 476477-34-6 CAPLUS


CN 1H-Imidazole-4-sulfonamide, N-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]-1-methyl- (CA INDEX NAME)






RN 476477-35-7 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(dimethylamino)-1-methylethyl]- (CA INDEX NAME)




RN 476477-36-8 CAPLUS

CN Urea, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N'-(3-(dimethylamino)propyl)- (CA INDEX NAME)




RN 476477-37-9 CAPLUS

CN Urea, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N'-(2-hydroxyethyl)- (CA INDEX NAME)




RN 476477-38-0 CAPLUS

CN Carbamic acid, [4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 476477-40-4 CAPLUS

CN Carbamic acid, [4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)




RN 476477-41-5 CAPLUS

CN Urea, N,N'-bis[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476477-42-6 CAPLUS

CN Carbamic acid, dimethyl-, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl ester (9CI) (CA INDEX NAME)




RN 476477-43-7 CAPLUS

CN Quinoline, 7-bromo-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 476477-44-8 CAPLUS

CN 6-Quinolinemethanol, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- $\alpha,\alpha$ -dimethyl- (CA INDEX NAME)




RN 476477-45-9 CAPLUS

CN Quinoline, 7-[(3-chloropropyl)thio]-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-47-1 CAPLUS

CN 7-Quinolinol, 8-chloro-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-48-2 CAPLUS

CN 7-Quinolinol, 8-bromo-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-50-6 CAPLUS

CN Quinoline, 7-bromo-4-[5,6-dihydro-4-methoxy-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-51-7 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazol-4-amine, 3-(7-bromo-4-quinolinyl)-5,6-dihydro-N-methyl-2-(2-pyridinyl)- (CA INDEX NAME)




RN 476477-53-9 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazol-4-one, 3-(7-bromo-4-quinolinyl)-5,6-dihydro-2-(2-pyridinyl)- (CA INDEX NAME)




RN 476477-54-0 CAPLUS

CN Benzonitrile, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




RN 476477-56-2 CAPLUS

CN Benzamide, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




RN 476477-58-4 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[(6-methyl-3-pyridazinyl)oxy]- (CA INDEX NAME)




RN 476477-60-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butoxy]- (CA INDEX NAME)




RN 476477-65-3 CAPLUS

CN Benzenemethanamine, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 476477-66-4 CAPLUS

CN 2(1H)-Quinolinone, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 476477-67-5 CAPLUS

CN 7-Quinolinol, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




IT 476477-68-6P, 6-Methoxy-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-ol 476477-70-0P, 4-[6-Methyl-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476477-71-1P, 3-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-6-yl]propionic acid methyl ester 476477-72-2P, 7-Amino-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476477-73-3P, N,N-Dimethyl-3-[4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]propionamide 476477-74-4P, N-[3-[4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]propyl]acetamide 476477-75-5P, N-Acetyl-N-[4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]acetamide 476477-78-8P, Methyl [3-[[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxy]propyl]amine 476477-80-2P, 7-(Piperidin-4-yloxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476477-84-6P, 7-(1-Methylpyrrolidin-3-

ylmethoxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476477-85-7P, 7-(1-Methylpiperidin-4-ylmethoxy)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476477-86-8P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (2-dimethylamino-1,1-dimethylethyl)amide 476477-94-8P, 3-[4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxazolidin-2-one 476477-95-9P, 1-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]imidazolidin-2-one 476477-96-0P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-7-(pyridin-4-ylmethoxy)quinoline 476477-97-1P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-7-(3-(pyridin-3-yl)propoxy)quinoline 476477-98-2P, 7-(4,5-Dihydro-1H-imidazol-2-yl)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476478-01-0P, 4-[2-(6-Vinylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476478-03-2P, 3-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-6-yl]acrylic acid 476478-04-3P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-carboxylic acid (2-acetylaminoethyl)amide 476478-05-4P, (R)-7-[2-(1-Methylpyrrolidin-2-yl)ethoxy]-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476478-06-5P 476478-07-6P 476478-08-7P 476478-09-8P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (3-(pyrrolidin-1-yl)propyl)amide  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (hetero)aromatic substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles as TGF- $\beta$  signal transduction inhibitors)


RN 476477-68-6 CAPLUS

CN 7-Quinolinol, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-methoxy- (CA INDEX NAME)




RN 476477-70-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-6-methyl-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-71-1 CAPLUS

CN 6-Quinolinepropanoic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, methyl ester (CA INDEX NAME)




RN 476477-72-2 CAPLUS

CN 7-Quinolinamine, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-73-3 CAPLUS

CN 7-Quinolinepropanamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N,N-dimethyl- (CA INDEX NAME)



RN 476477-74-4 CAPLUS


CN Acetamide, N-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]- (CA INDEX NAME)






RN 476477-75-5 CAPLUS

CN Acetamide, N-acetyl-N-[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476477-78-8 CAPLUS

CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N-methyl- (CA INDEX NAME)




RN 476477-80-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-piperidinyloxy)- (CA INDEX NAME)




RN 476477-84-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[(1-methyl-3-pyrrolidinyloxy)methoxy]- (CA INDEX NAME)




RN 476477-85-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-  
[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)




RN 476477-86-8 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(dimethylamino)-1,1-dimethylethyl]- (CA INDEX NAME)




RN 476477-94-8 CAPLUS

CN 2-Oxazolidinone, 3-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476477-95-9 CAPLUS

CN 2-Imidazolidinone, 1-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476477-96-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-pyridinylmethoxy)- (CA INDEX NAME)




RN 476477-97-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(3-pyridinyl)propoxy]- (CA INDEX NAME)




RN 476477-98-2 CAPLUS

CN Quinoline, 7-(4,5-dihydro-1H-imidazol-2-yl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476478-01-0 CAPLUS

CN Quinoline, 4-[2-(6-ethenyl-2-pyridinyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476478-03-2 CAPLUS

CN 2-Propenoic acid, 3-[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinyl]- (CA INDEX NAME)



RN 476478-04-3 CAPLUS


CN 7-Quinolinecarboxamide, N-[2-(acetylamino)ethyl]-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 476478-05-4 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-[(2R)-1-methyl-2-pyrrolidinyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 476478-06-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-1-oxido-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476478-07-6 CAPLUS

CN Quinoline, 7-(3-chloropropoxy)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 1-oxide (CA INDEX NAME)




RN 476478-08-7 CAPLUS

CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-oxido-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 476478-09-8 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)



IT 476476-80-9, [4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]acetic acid 476477-23-3,


7-Bromo-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476477-79-9 476478-02-1,  
4-[2-(6-Chloropyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of (hetero)aromatic substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles as TGF- $\beta$  signal transduction inhibitors)


RN 476476-80-9 CAPLUS

CN Acetic acid, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




RN 476477-23-3 CAPLUS

CN Quinoline, 7-bromo-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-79-9 CAPLUS

CN Carbamic acid, [3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]-, 1,1-dimethylethyl ester (9CI)  
(CA INDEX NAME)



RN 476478-02-1 CAPLUS

CN Quinoline, 4-[2-(6-chloro-2-pyridinyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




IT 476473-77-5F, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-7-[3-(pyrimidin-2-ylsulfanyl)propoxy]quinoline 476473-81-1F 476473-82-2F, 7-[3-(4-Chlorophenylsulfanyl)propoxy]-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476473-83-3F, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-7-[3-(4-(pyrimidin-2-yl)piperazin-1-yl)propoxy]quinoline 476473-86-6F, 7-[3-[4-(2-Methoxyphenyl)piperazin-1-yl]propoxy]-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476473-87-7F, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(((pyridin-2-yl)methyl)sulfanyl)propoxy]quinoline 476473-91-3F, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-carboxylic acid 476474-00-7F, 4-[2-(6-Chloromethylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-02-9F, Methanesulfonic acid [2-(pyridin-2-yl)-3-(quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-6-yl]methyl ester 476474-10-9F, 4-[4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]piperidine-1-carboxylic acid tert-butyl ester 476474-12-1F, (Pyridin-2-yl) [3-[[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propyl]amine 476474-13-2F, 7-(5-Chloropentyloxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476474-14-3F, 3-[[[4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxy]methyl]pyrrolidine-1-carboxylic acid benzyl ester 476474-15-4F, Dimethyl [5-[[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxy]penty]amine 476474-16-5F, Methyl [5-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yloxy]penty]amine 476474-17-6F, 1,3-Bis[3-[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]propyl]-1,3-dihydrobenzimidazol-2-one 476474-18-7F, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-2-carboxylic acid ethyl ester 476474-24-5F, [2-Methyl-2-[[4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carbonyl]amino]propyl]carbamic acid tert-butyl ester 476474-26-7F, 6-((tert-Butoxycarbonyl)amino)-2-[[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-carbonyl]amino]hexanoic acid methyl ester 476474-29-0F, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-((tetrahydrofuran-2-yl)methoxy)quinoline 476474-30-3F

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of (hetero)aromatic substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles as TGF- $\beta$  signal transduction inhibitors)


RN 476473-77-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(2-pyrimidinylthio)propoxy]- (CA INDEX NAME)




RN 476473-81-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-[(1-methyl-1H-imidazol-2-yl)thio]propoxy]- (CA INDEX NAME)




RN 476473-82-2 CAPLUS

CN Quinoline, 7-[3-[(4-chlorophenyl)thio]propoxy]-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 476473-83-3 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-[(2-pyrimidinyl)-1-piperazinyl]propoxy]- (CA INDEX NAME)



RN 476473-86-6 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-[(4-methoxyphenyl)-1-piperazinyl]propoxy]- (CA INDEX NAME)






RN 476473-87-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-[(2-pyridinylmethyl)thio]propoxy]- (CA INDEX NAME)




RN 476473-91-3 CAPLUS

CN 7-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-00-7 CAPLUS

CN Quinoline, 4-[2-[6-(chloromethyl)-2-pyridinyl]-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-02-9 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole-6-methanol, 5,6-dihydro-2-(2-pyridinyl)-3-(4-quinolinyl)-, 6-methanesulfonate (CA INDEX NAME)




RN 476474-10-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 476474-12-1 CAPLUS

CN 2-Pyridinamine, N-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]- (CA INDEX NAME)



RN 476474-13-2 CAPLUS


CN Quinoline, 7-[(5-chloropentyl)oxy]-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 476474-14-3 CAPLUS


CN 1-Pyrrolidinecarboxylic acid, 3-[[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-

pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy)methyl]-, phenylmethyl ester  
(CA INDEX NAME)




RN 476474-15-4 CAPLUS

CN 1-Pentanamine, 5-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 476474-16-5 CAPLUS

CN 1-Pentanamine, 5-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N-methyl- (CA INDEX NAME)




RN 476474-17-6 CAPLUS

CN 2H-Benzimidazol-2-one, 1,3-bis[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]-1,3-dihydro- (CA INDEX NAME)




RN 476474-18-7 CAPLUS

CN 2-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, ethyl ester (CA INDEX NAME)



RN 476474-24-5 CAPLUS


CN Carbamic acid, [2-[[[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]carbonyl]amino]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 476474-26-7 CAPLUS


CN L-Lysine, N2-[[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]carbonyl]-N6-[(1,1-dimethylethoxy)carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 476474-29-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-  
[(tetrahydro-2-furanyl)methoxy]- (CA INDEX NAME)



RN 476474-30-3 CAPLUS

CN Quinoline, 7,7'-[1,5-pentanediylobis(oxy)]bis[4-[5,6-dihydro-2-(2-  
pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> end

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

79.46

460.05

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

	ENTRY	SESSION
CA SUBSCRIBER PRICE	-8.00	-8.00

STN INTERNATIONAL LOGOFF AT 18:13:33 ON 17 JUN 2008